6oim › Citations

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR
Nature 575 217-223 (2019)
Cited: 801 times
EuropePMC logo PMID: 31666701

Abstract

KRAS is the most frequently mutated oncogene in cancer and encodes a key signalling protein in tumours1,2. The KRAS(G12C) mutant has a cysteine residue that has been exploited to design covalent inhibitors that have promising preclinical activity3-5. Here we optimized a series of inhibitors, using novel binding interactions to markedly enhance their potency and selectivity. Our efforts have led to the discovery of AMG 510, which is, to our knowledge, the first KRAS(G12C) inhibitor in clinical development. In preclinical analyses, treatment with AMG 510 led to the regression of KRASG12C tumours and improved the anti-tumour efficacy of chemotherapy and targeted agents. In immune-competent mice, treatment with AMG 510 resulted in a pro-inflammatory tumour microenvironment and produced durable cures alone as well as in combination with immune-checkpoint inhibitors. Cured mice rejected the growth of isogenic KRASG12D tumours, which suggests adaptive immunity against shared antigens. Furthermore, in clinical trials, AMG 510 demonstrated anti-tumour activity in the first dosing cohorts and represents a potentially transformative therapy for patients for whom effective treatments are lacking.

Reviews - 6oim mentioned but not cited (19)

  1. RAS-targeted therapies: is the undruggable drugged? Moore AR, Rosenberg SC, McCormick F, Malek S. Nat Rev Drug Discov 19 533-552 (2020)
  2. Biology, pathology, and therapeutic targeting of RAS. Rhett JM, Khan I, O'Bryan JP. Adv Cancer Res 148 69-146 (2020)
  3. Progress in the therapeutic inhibition of Cdc42 signalling. Murphy NP, Mott HR, Owen D. Biochem Soc Trans 49 1443-1456 (2021)
  4. Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families. Li L, Meyer C, Zhou ZW, Elmezayen A, Westover K. J Mol Biol 434 167626 (2022)
  5. Mapping the binding sites of challenging drug targets. Wakefield AE, Kozakov D, Vajda S. Curr Opin Struct Biol 75 102396 (2022)
  6. Advanced approaches of developing targeted covalent drugs. Gai C, Harnor SJ, Zhang S, Cano C, Zhuang C, Zhao Q. RSC Med Chem 13 1460-1475 (2022)
  7. Advances in covalent drug discovery. Boike L, Henning NJ, Nomura DK. Nat Rev Drug Discov 21 881-898 (2022)
  8. Covalent inhibitors: a rational approach to drug discovery. Sutanto F, Konstantinidou M, Dömling A. RSC Med Chem 11 876-884 (2020)
  9. Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg. Rosen JC, Sacher A, Tsao MS. Ther Adv Med Oncol 15 17588359231160141 (2023)
  10. Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes. Hartung IV, Rudolph J, Mader MM, Mulder MPC, Workman P. J Med Chem 66 9297-9312 (2023)
  11. Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets. Lee J, Park SB. Pharmaceuticals (Basel) 15 1478 (2022)
  12. KRasG12C inhibitors in clinical trials: a short historical perspective. Goebel L, Müller MP, Goody RS, Rauh D. RSC Med Chem 11 760-770 (2020)
  13. Reactive chemistry for covalent probe and therapeutic development. Grams RJ, Hsu KL. Trends Pharmacol Sci 43 249-262 (2022)
  14. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift. Nyíri K, Koppány G, Vértessy BG. Cancer Metastasis Rev 39 1091-1105 (2020)
  15. Targeting KRAS in PDAC: A New Way to Cure It? He Q, Liu Z, Wang J. Cancers (Basel) 14 4982 (2022)
  16. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, Zhang W, Qin JJ. Mol Cancer 21 159 (2022)
  17. Targeting protein conformations with small molecules to control protein complexes. Zacharioudakis E, Gavathiotis E. Trends Biochem Sci 47 1023-1037 (2022)
  18. Targeting the "undruggable" RAS with biologics. Whaby M, Khan I, O'Bryan JP. Adv Cancer Res 153 237-266 (2022)
  19. Technologies for Direct Detection of Covalent Protein-Drug Adducts. Mons E, Kim RQ, Mulder MPC. Pharmaceuticals (Basel) 16 547 (2023)

Articles - 6oim mentioned but not cited (26)

  1. Acquired Resistance to KRASG12C Inhibition in Cancer. Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Jänne PA, Aguirre AJ. N Engl J Med 384 2382-2393 (2021)
  2. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB. Cancer Discov 11 1913-1922 (2021)
  3. KRAS is vulnerable to reversible switch-II pocket engagement in cells. Vasta JD, Peacock DM, Zheng Q, Walker JA, Zhang Z, Zimprich CA, Thomas MR, Beck MT, Binkowski BF, Corona CR, Robers MB, Shokat KM. Nat Chem Biol 18 596-604 (2022)
  4. Cryo-EM structure determination of small therapeutic protein targets at 3 Å-resolution using a rigid imaging scaffold. Castells-Graells R, Meador K, Arbing MA, Sawaya MR, Gee M, Cascio D, Gleave E, Debreczeni JÉ, Breed J, Leopold K, Patel A, Jahagirdar D, Lyons B, Subramaniam S, Phillips C, Yeates TO. Proc Natl Acad Sci U S A 120 e2305494120 (2023)
  5. KRAS G12C fragment screening renders new binding pockets. Mathieu M, Steier V, Fassy F, Delorme C, Papin D, Genet B, Duffieux F, Bertrand T, Delarbre L, Le-Borgne H, Parent A, Didier P, Marquette JP, Lowinski M, Houtmann J, Lamberton A, Debussche L, Alexey R. Small GTPases 13 225-238 (2022)
  6. KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations. Pantsar T. Sci Rep 10 11992 (2020)
  7. In Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecular Dynamics Simulation and Markov State Model Analysis. Tu G, Liu Q, Qiu Y, Leung EL, Yao X. Int J Mol Sci 23 13845 (2022)
  8. A New View of Activating Mutations in Cancer. Nussinov R, Tsai CJ, Jang H. Cancer Res 82 4114-4123 (2022)
  9. A Structure is Worth a Thousand Words: New Insights for RAS and RAF Regulation. Simanshu DK, Morrison DK. Cancer Discov 12 899-912 (2022)
  10. A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors. Feng S, Callow MG, Fortin JP, Khan Z, Bray D, Costa M, Shi Z, Wang W, Evangelista M. Proc Natl Acad Sci U S A 119 e2120512119 (2022)
  11. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models. Nakayama A, Nagashima T, Nishizono Y, Kuramoto K, Mori K, Homboh K, Yuri M, Shimazaki M. Br J Cancer 126 744-753 (2022)
  12. Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S). Zhang Z, Guiley KZ, Shokat KM. Nat Chem Biol 18 1177-1183 (2022)
  13. Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study. Srisongkram T, Weerapreeyakul N. Int J Mol Sci 24 669 (2022)
  14. Hitting KRAS When It's Down. Gabizon R, London N. J Med Chem 63 6677-6678 (2020)
  15. Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report. Blanchard-Rohner G, Ragotte RJ, Junker AK, Sharma M, Del Bel KL, Lu HY, Erdle S, Chomyn A, Gill H, Tucker LB, Schreiber RA, Rozmus J, Biggs CM, Hildebrand KJ, Wu J, Stockler-Ipsiroglu S, Turvey SE. BMC Pediatr 21 45 (2021)
  16. In Silico Evaluation of the Thr58-Associated Conserved Water with KRAS Switch-II Pocket Binders. Leini R, Pantsar T. J Chem Inf Model 63 1490-1505 (2023)
  17. Inhibition of RAS: proven and potential vulnerabilities. Zuberi M, Khan I, O'Bryan JP. Biochem Soc Trans 48 1831-1841 (2020)
  18. Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. Yenerall P, Kollipara RK, Avila K, Peyton M, Eide CA, Bottomly D, McWeeney SK, Liu Y, Westover KD, Druker BJ, Minna JD, Kittler R. Cancer Res 81 4685-4695 (2021)
  19. Mechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C. Zhuang H, Fan J, Li M, Zhang H, Yang X, Lin L, Lu S, Wang Q, Liu Y. Front Oncol 12 915512 (2022)
  20. Modeling receptor flexibility in the structure-based design of KRASG12C inhibitors. Zhu K, Li C, Wu KY, Mohr C, Li X, Lanman B. J Comput Aided Mol Des 36 591-604 (2022)
  21. Molecular docking analysis of KRAS inhibitors for cancer management. J Hakeem I, Alsharif FH, Aljadani M, Fahad Alabbas I, Faqihi MS, Aloufi AH, Almutairi WA, Akber AH, Alam Q. Bioinformation 19 411-416 (2023)
  22. Case Reports Molecular docking analysis reveals differential binding affinities of multiple classes of selective inhibitors towards cancer-associated KRAS mutants. Mullaguri SC, Akula S, Sahoo PS, Ashireddygari VR, Mupparapu V, Silveri R, Prasad Burra VLS, Kancha RK. 3 Biotech 12 343 (2022)
  23. Multicomponent reaction-derived covalent inhibitor space. Sutanto F, Shaabani S, Neochoritis CG, Zarganes-Tzitzikas T, Patil P, Ghonchepour E, Dömling A. Sci Adv 7 (2021)
  24. RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site. Haza KZ, Martin HL, Rao A, Turner AL, Saunders SE, Petersen B, Tiede C, Tipping K, Tang AA, Ajayi M, Taylor T, Harvey M, Fishwick KM, Adams TL, Gaule TG, Trinh CH, Johnson M, Breeze AL, Edwards TA, McPherson MJ, Tomlinson DC. Nat Commun 12 4045 (2021)
  25. SMALL MOLECULE IMAGING AGENT FOR MUTANT KRAS G12C. Koch PD, Quintana J, Ahmed M, Kohler RH, Weissleder R. Adv Ther (Weinh) 4 2000290 (2021)
  26. Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation. Li Y, Han L, Zhang Z. Comput Struct Biotechnol J 20 1056-1067 (2022)


Reviews citing this publication (316)

  1. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Koppula P, Zhuang L, Gan B. Protein Cell 12 599-620 (2021)
  2. Regulation and modulation of antitumor immunity in pancreatic cancer. Leinwand J, Miller G. Nat Immunol 21 1152-1159 (2020)
  3. Immune modulatory effects of oncogenic KRAS in cancer. Hamarsheh S, Groß O, Brummer T, Zeiser R. Nat Commun 11 5439 (2020)
  4. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. Cancer Treat Rev 84 101974 (2020)
  5. Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic. Hu Z, Crews CM. Chembiochem 23 e202100270 (2022)
  6. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Hofmann MH, Gerlach D, Misale S, Petronczki M, Kraut N. Cancer Discov 12 924-937 (2022)
  7. The Metabolic Landscape of RAS-Driven Cancers from biology to therapy. Mukhopadhyay S, Vander Heiden MG, McCormick F. Nat Cancer 2 271-283 (2021)
  8. Immune escape and immunotherapy of acute myeloid leukemia. Vago L, Gojo I. J Clin Invest 130 1552-1564 (2020)
  9. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Wood LD, Canto MI, Jaffee EM, Simeone DM. Gastroenterology 163 386-402.e1 (2022)
  10. Advances in targeting 'undruggable' transcription factors with small molecules. Henley MJ, Koehler AN. Nat Rev Drug Discov 20 669-688 (2021)
  11. Sotorasib: First Approval. Blair HA. Drugs 81 1573-1579 (2021)
  12. Targeting pan-essential genes in cancer: Challenges and opportunities. Chang L, Ruiz P, Ito T, Sellers WR. Cancer Cell 39 466-479 (2021)
  13. Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. Indini A, Rijavec E, Ghidini M, Cortellini A, Grossi F. Pharmaceutics 13 653 (2021)
  14. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. König D, Savic Prince S, Rothschild SI. Cancers (Basel) 13 804 (2021)
  15. Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation. Bond MJ, Crews CM. RSC Chem Biol 2 725-742 (2021)
  16. PROTAC targeted protein degraders: the past is prologue. Békés M, Langley DR, Crews CM. Nat Rev Drug Discov 21 181-200 (2022)
  17. KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas. Gu M, Xu T, Chang P. Ther Adv Med Oncol 13 17588359211006950 (2021)
  18. MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Moon H, Ro SW. Cancers (Basel) 13 3026 (2021)
  19. Mechanisms of Resistance to KRASG12C-Targeted Therapy. Akhave NS, Biter AB, Hong DS. Cancer Discov 11 1345-1352 (2021)
  20. Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls. Esposito Abate R, Frezzetti D, Maiello MR, Gallo M, Camerlingo R, De Luca A, De Cecio R, Morabito A, Normanno N. Cancers (Basel) 12 E3804 (2020)
  21. Targeting KRAS: The Elephant in the Room of Epithelial Cancers. Merz V, Gaule M, Zecchetto C, Cavaliere A, Casalino S, Pesoni C, Contarelli S, Sabbadini F, Bertolini M, Mangiameli D, Milella M, Fedele V, Melisi D. Front Oncol 11 638360 (2021)
  22. Emerging strategies to target RAS signaling in human cancer therapy. Chen K, Zhang Y, Qian L, Wang P. J Hematol Oncol 14 116 (2021)
  23. Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications. Cao L, Wu J, Qu X, Sheng J, Cui M, Liu S, Huang X, Xiang Y, Li B, Zhang X, Cui R. J Exp Clin Cancer Res 39 267 (2020)
  24. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. Chevallier M, Borgeaud M, Addeo A, Friedlaender A. World J Clin Oncol 12 217-237 (2021)
  25. Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications. Reese M, Dhayat SA. J Hematol Oncol 14 141 (2021)
  26. The Frequency of Ras Mutations in Cancer. Prior IA, Hood FE, Hartley JL. Cancer Res 80 2969-2974 (2020)
  27. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Baiocchi L, Sato K, Ekser B, Kennedy L, Francis H, Ceci L, Lenci I, Alvaro D, Franchitto A, Onori P, Gaudio E, Wu C, Chakraborty S, Glaser S, Alpini G. Expert Opin Investig Drugs 30 365-375 (2021)
  28. Clinical cancer genomic profiling. Chakravarty D, Solit DB. Nat Rev Genet 22 483-501 (2021)
  29. Drug resistance in targeted cancer therapies with RAF inhibitors. Degirmenci U, Yap J, Sim YRM, Qin S, Hu J. Cancer Drug Resist 4 665-683 (2021)
  30. Epidemiology of brain metastases and leptomeningeal disease. Lamba N, Wen PY, Aizer AA. Neuro Oncol 23 1447-1456 (2021)
  31. Hotspots of Human Mutation. Nesta AV, Tafur D, Beck CR. Trends Genet 37 717-729 (2021)
  32. Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. Barnestein R, Galland L, Kalfeist L, Ghiringhelli F, Ladoire S, Limagne E. Oncoimmunology 11 2120676 (2022)
  33. Immunotherapy, Inflammation and Colorectal Cancer. Lichtenstern CR, Ngu RK, Shalapour S, Karin M. Cells 9 (2020)
  34. Inhibition of Nonfunctional Ras. Nussinov R, Jang H, Gursoy A, Keskin O, Gaponenko V. Cell Chem Biol 28 121-133 (2021)
  35. Precision oncology in metastatic colorectal cancer - from biology to medicine. Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Nat Rev Clin Oncol 18 506-525 (2021)
  36. Recent insights into the biology of pancreatic cancer. Yao W, Maitra A, Ying H. EBioMedicine 53 102655 (2020)
  37. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Wu Q, Qian W, Sun X, Jiang S. J Hematol Oncol 15 143 (2022)
  38. Targeted protein degradation: A promise for undruggable proteins. Samarasinghe KTG, Crews CM. Cell Chem Biol 28 934-951 (2021)
  39. KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges. Ceddia S, Landi L, Cappuzzo F. Int J Mol Sci 23 9391 (2022)
  40. A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer. Heppner DE, Eck MJ. Protein Sci 30 1535-1553 (2021)
  41. Drugging the Undruggable: Advances on RAS Targeting in Cancer. Molina-Arcas M, Samani A, Downward J. Genes (Basel) 12 899 (2021)
  42. Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications. Bergholz JS, Wang Q, Kabraji S, Zhao JJ. Clin Cancer Res 26 5557-5566 (2020)
  43. KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup. Xie M, Xu X, Fan Y. Front Oncol 11 672612 (2021)
  44. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges. Tang D, Kroemer G, Kang R. Mol Cancer 20 128 (2021)
  45. Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease. Sherman DJ, Li J. Molecules 25 (2020)
  46. Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Yip HYK, Papa A. Cells 10 659 (2021)
  47. Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer. Sunaga N, Miura Y, Kasahara N, Sakurai R. Cancers (Basel) 13 5956 (2021)
  48. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Wang H, Guo M, Wei H, Chen Y. Signal Transduct Target Ther 8 92 (2023)
  49. The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. Elsayed M, Abdelrahim M. Biomedicines 9 389 (2021)
  50. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer. Vonderheide RH, Bear AS. Front Immunol 11 605619 (2020)
  51. Emerging RAS-directed therapies for cancer. Conroy M, Cowzer D, Kolch W, Duffy AG. Cancer Drug Resist 4 543-558 (2021)
  52. Fragment-based covalent ligand discovery. Lu W, Kostic M, Zhang T, Che J, Patricelli MP, Jones LH, Chouchani ET, Gray NS. RSC Chem Biol 2 354-367 (2021)
  53. Harnessing multimodal data integration to advance precision oncology. Boehm KM, Khosravi P, Vanguri R, Gao J, Shah SP. Nat Rev Cancer 22 114-126 (2022)
  54. Investigating Cryptic Binding Sites by Molecular Dynamics Simulations. Kuzmanic A, Bowman GR, Juarez-Jimenez J, Michel J, Gervasio FL. Acc Chem Res 53 654-661 (2020)
  55. KRAS G12C Mutations in NSCLC: From Target to Resistance. Addeo A, Banna GL, Friedlaender A. Cancers (Basel) 13 2541 (2021)
  56. KRAS mutation in pancreatic cancer. Luo J. Semin Oncol 48 10-18 (2021)
  57. KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC). Chen H, Zhao J. Thorac Cancer 11 3425-3435 (2020)
  58. Pancreas cancer: Therapeutic trials in metastatic disease. Smithy JW, O'Reilly EM. J Surg Oncol 123 1475-1488 (2021)
  59. Pancreatic Cancer and Its Microenvironment-Recent Advances and Current Controversies. Stopa KB, Kusiak AA, Szopa MD, Ferdek PE, Jakubowska MA. Int J Mol Sci 21 (2020)
  60. Targeting BRAF and RAS in Colorectal Cancer. Bellio H, Fumet JD, Ghiringhelli F. Cancers (Basel) 13 2201 (2021)
  61. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. Yuan J, Dong X, Yap J, Hu J. J Hematol Oncol 13 113 (2020)
  62. The Role of Wild-Type RAS in Oncogenic RAS Transformation. Sheffels E, Kortum RL. Genes (Basel) 12 662 (2021)
  63. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Nat Rev Cancer 22 323-339 (2022)
  64. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Schenk EL, Patil T, Pacheco J, Bunn PA. Oncologist 26 e454-e472 (2021)
  65. A Gene Expression High-Throughput Screen (GE-HTS) for Coordinated Detection of Functionally Similar Effectors in Cancer. Rao C, Huisman DH, Vieira HM, Frodyma DE, Neilsen BK, Chakraborty B, Hight SK, White MA, Fisher KW, Lewis RE. Cancers (Basel) 12 E3143 (2020)
  66. Advances in Immunosuppressive Agents Based on Signal Pathway. Xu Z, Chu M. Front Pharmacol 13 917162 (2022)
  67. CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Harvey JB, Phan LH, Villarreal OE, Bowser JL. Front Immunol 11 508 (2020)
  68. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer. Regel I, Mayerle J, Mahajan UM. Cancers (Basel) 12 (2020)
  69. Genetic and biological hallmarks of colorectal cancer. Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genes Dev 35 787-820 (2021)
  70. If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer. Köhler J, Jänne PA. Int J Mol Sci 22 3025 (2021)
  71. Mechanism of activation and the rewired network: New drug design concepts. Nussinov R, Zhang M, Maloney R, Tsai CJ, Yavuz BR, Tuncbag N, Jang H. Med Res Rev 42 770-799 (2022)
  72. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Cancers (Basel) 13 2638 (2021)
  73. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Cancers (Basel) 12 (2020)
  74. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease. Michelotti A, de Scordilli M, Bertoli E, De Carlo E, Del Conte A, Bearz A. Int J Mol Sci 23 6748 (2022)
  75. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma. Singh RR, O'Reilly EM. Drugs 80 647-669 (2020)
  76. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. Stein MK, Oluoha O, Patel K, VanderWalde A. J Pers Med 11 518 (2021)
  77. Rational combinations of targeted cancer therapies: background, advances and challenges. Jin H, Wang L, Bernards R. Nat Rev Drug Discov 22 213-234 (2023)
  78. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Zhu G, Pei L, Xia H, Tang Q, Bi F. Mol Cancer 20 143 (2021)
  79. Strategies to tackle RAS-mutated metastatic colorectal cancer. Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patanè DA, Pani A, Scaglione F, Siena S, Sartore-Bianchi A. ESMO Open 6 100156 (2021)
  80. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. Leroux C, Konstantinidou G. Cancers (Basel) 13 799 (2021)
  81. Targeting KRAS G12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments. Ji J, Wang C, Fakih M. Onco Targets Ther 15 747-756 (2022)
  82. Targeting the undruggable oncogenic KRAS: the dawn of hope. Asimgil H, Ertetik U, Çevik NC, Ekizce M, Doğruöz A, Gökalp M, Arık-Sever E, Istvanffy R, Friess H, Ceyhan GO, Demir IE. JCI Insight 7 e153688 (2022)
  83. The Cytomegalovirus Protein Kinase pUL97:Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting. Steingruber M, Marschall M. Microorganisms 8 (2020)
  84. Tumor-intrinsic determinants of immunogenic cell death modalities. Workenhe ST, Pol J, Kroemer G. Oncoimmunology 10 1893466 (2021)
  85. 40 Years of RAS-A Historic Overview. Fernández-Medarde A, De Las Rivas J, Santos E. Genes (Basel) 12 681 (2021)
  86. A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished. Ning W, Yang Z, Kocher GJ, Dorn P, Peng RW. Cancers (Basel) 14 390 (2022)
  87. Advances in the management of pancreatic ductal adenocarcinoma. O'Kane GM, Ladak F, Gallinger S. CMAJ 193 E844-E851 (2021)
  88. Autophagy Inhibition in BRAF-Driven Cancers. Foth M, McMahon M. Cancers (Basel) 13 3498 (2021)
  89. Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, Proto C, Ferrara R, Galli G, De Toma A, Genova C, Jereczek-Fossa BA, Braud F, Garassino MC, Rebuzzi SE. Cancers (Basel) 13 1300 (2021)
  90. Drugging KRAS: current perspectives and state-of-art review. Parikh K, Banna G, Liu SV, Friedlaender A, Desai A, Subbiah V, Addeo A. J Hematol Oncol 15 152 (2022)
  91. GLOBAL AND TARGETED PROFILING OF GTP-BINDING PROTEINS IN BIOLOGICAL SAMPLES BY MASS SPECTROMETRY. Huang M, Wang Y. Mass Spectrom Rev 40 215-235 (2021)
  92. Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer. Hijazo-Pechero S, Alay A, Marín R, Vilariño N, Muñoz-Pinedo C, Villanueva A, Santamaría D, Nadal E, Solé X. Cancers (Basel) 13 4734 (2021)
  93. Glycogen Synthase Kinase 3β in Cancer Biology and Treatment. Domoto T, Uehara M, Bolidong D, Minamoto T. Cells 9 (2020)
  94. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Imaoka H, Sasaki M, Hashimoto Y, Watanabe K, Miyazawa S, Shibuki T, Mitsunaga S, Ikeda M. Diagnostics (Basel) 11 1195 (2021)
  95. KRAS G12C inhibition and innate immune targeting. Tani T, Kitajima S, Conway EB, Knelson EH, Barbie DA. Expert Opin Ther Targets 25 167-174 (2021)
  96. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. Gu M, Gao Y, Chang P. Cancers (Basel) 13 2429 (2021)
  97. KRAS mutation: from undruggable to druggable in cancer. Huang L, Guo Z, Wang F, Fu L. Signal Transduct Target Ther 6 386 (2021)
  98. Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives. Miyabayashi K, Nakagawa H, Koike K. Front Oncol 11 682872 (2021)
  99. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. Wu J, Lin Z. Int J Mol Sci 23 15056 (2022)
  100. Novel Perspectives in Pseudomyxoma Peritonei Treatment. Sommariva A, Tonello M, Rigotto G, Lazzari N, Pilati P, Calabrò ML. Cancers (Basel) 13 5965 (2021)
  101. Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development. Arnal-Estapé A, Foggetti G, Starrett JH, Nguyen DX, Politi K. Cold Spring Harb Perspect Med 11 a037820 (2021)
  102. Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives. Césaire M, Montanari J, Curcio H, Lerouge D, Gervais R, Demontrond P, Balosso J, Chevalier F. Cancers (Basel) 14 2829 (2022)
  103. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Hayashi H, Higashi T, Miyata T, Yamashita YI, Baba H. Ann Gastroenterol Surg 5 457-466 (2021)
  104. Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer. Li Y, Hu L, Peng X, Xu H, Tang B, Xu C. Cancer Drug Resist 5 129-146 (2022)
  105. SOS2 Comes to the Fore: Differential Functionalities in Physiology and Pathology. Baltanás FC, García-Navas R, Santos E. Int J Mol Sci 22 6613 (2021)
  106. Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators. Qiu Y, Wang Y, Chai Z, Ni D, Li X, Pu J, Chen J, Zhang J, Lu S, Lv C, Ji M. Acta Pharm Sin B 11 3433-3446 (2021)
  107. Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer. Pacini L, Jenks AD, Lima NC, Huang PH. Cells 10 1154 (2021)
  108. Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors. Dias Carvalho P, Machado AL, Martins F, Seruca R, Velho S. Cancers (Basel) 11 (2019)
  109. Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. Turpin A, Neuzillet C, Colle E, Dusetti N, Nicolle R, Cros J, de Mestier L, Bachet JB, Hammel P. Ther Adv Med Oncol 14 17588359221118019 (2022)
  110. An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. Tateo V, Manuzzi L, Parisi C, De Giglio A, Campana D, Pantaleo MA, Lamberti G. Pharmaceuticals (Basel) 14 316 (2021)
  111. An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer. von Karstedt S, Walczak H. Cell Death Discov 6 14 (2020)
  112. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, Lin R, He WL, Cai SR, He YL, Ye JN. Gastroenterol Rep (Oxf) 8 179-191 (2020)
  113. Antitumor pharmacological research in the era of personalized medicine. Huang M, Geng MY, Ding J. Acta Pharmacol Sin 43 3015-3020 (2022)
  114. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L. Nat Rev Clin Oncol 20 143-159 (2023)
  115. Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Digiacomo G, Volta F, Garajova I, Balsano R, Cavazzoni A. Life (Basel) 11 843 (2021)
  116. Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Puccini A, Seeber A, Berger MD. Cancers (Basel) 14 4828 (2022)
  117. Blocking K-Ras Interaction With the Plasma Membrane Is a Tractable Therapeutic Approach to Inhibit Oncogenic K-Ras Activity. Henkels KM, Rehl KM, Cho KJ. Front Mol Biosci 8 673096 (2021)
  118. CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries. Sreedurgalakshmi K, Srikar R, Rajkumari R. Cancer Gene Ther 28 566-580 (2021)
  119. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Bear AS, Vonderheide RH, O'Hara MH. Cancer Cell 38 788-802 (2020)
  120. Conquering oncogenic KRAS and its bypass mechanisms. Hou P, Wang YA. Theranostics 12 5691-5709 (2022)
  121. Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. Ashrafi A, Akter Z, Modareszadeh P, Modareszadeh P, Berisha E, Alemi PS, Chacon Castro MDC, Deese AR, Zhang L. Cancers (Basel) 14 4562 (2022)
  122. Current therapy of KRAS-mutant lung cancer. Ghimessy A, Radeczky P, Laszlo V, Hegedus B, Renyi-Vamos F, Fillinger J, Klepetko W, Lang C, Dome B, Megyesfalvi Z. Cancer Metastasis Rev 39 1159-1177 (2020)
  123. Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance. Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M. Cancers (Basel) 14 1321 (2022)
  124. Discovery through clinical sequencing in oncology. Donoghue MTA, Schram AM, Hyman DM, Taylor BS. Nat Cancer 1 774-783 (2020)
  125. Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification. Osaka N, Hirota Y, Ito D, Ikeda Y, Kamata R, Fujii Y, Chirasani VR, Campbell SL, Takeuchi K, Senda T, Sasaki AT. Front Mol Biosci 8 707439 (2021)
  126. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. McCubrey JA, Yang LV, Abrams SL, Steelman LS, Follo MY, Cocco L, Ratti S, Martelli AM, Augello G, Cervello M. Cells 11 2155 (2022)
  127. Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. Hintzen G, Dulat HJ, Rajkovic E. Front Oncol 12 892212 (2022)
  128. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward? Hasbullah HH, Musa M. Int J Mol Sci 22 11941 (2021)
  129. Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts. Dunnett-Kane V, Burkitt-Wright E, Blackhall FH, Malliri A, Evans DG, Lindsay CR. Ann Oncol 31 873-883 (2020)
  130. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy. Li J, Stanger BZ. Cancer Res 80 4037-4041 (2020)
  131. Identifying Novel Actionable Targets in Colon Cancer. Cerrito MG, Grassilli E. Biomedicines 9 579 (2021)
  132. Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Front Immunol 13 823618 (2022)
  133. Mechanisms driving the immunoregulatory function of cancer cells. van Weverwijk A, de Visser KE. Nat Rev Cancer 23 193-215 (2023)
  134. Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. Pook H, Pauklin S. Cancers (Basel) 13 4834 (2021)
  135. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. Cekani E, Epistolio S, Dazio G, Cefalì M, Wannesson L, Frattini M, Froesch P. Cancers (Basel) 14 4103 (2022)
  136. Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond. Shetu SA, James N, Rivera G, Bandyopadhyay D. Curr Issues Mol Biol 45 1914-1949 (2023)
  137. Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer. Guo D, Ye L, Wu W, Yu X, Jin K. Acta Biochim Biophys Sin (Shanghai) 55 923-937 (2023)
  138. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. Avery TY, Köhler N, Zeiser R, Brummer T, Ruess DA. Front Oncol 12 931774 (2022)
  139. Oncogenic KRAS: Signaling and Drug Resistance. Kim HJ, Lee HN, Jeong MS, Jang SB. Cancers (Basel) 13 5599 (2021)
  140. Oncogenic functions and therapeutic targeting of EphA2 in cancer. Wilson K, Shiuan E, Brantley-Sieders DM. Oncogene 40 2483-2495 (2021)
  141. Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. Truong LH, Pauklin S. Cancers (Basel) 13 5028 (2021)
  142. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Connor AA, Gallinger S. Nat Rev Cancer 22 131-142 (2022)
  143. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer. Qunaj L, May MS, Neugut AI, Herzberg BO. Front Oncol 13 1252516 (2023)
  144. Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Dillon M, Lopez A, Lin E, Sales D, Perets R, Jain P. Cancers (Basel) 13 5059 (2021)
  145. RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics. Kattan WE, Hancock JF. Biochem J 477 2893-2919 (2020)
  146. RAS pathway regulation in melanoma. Al Mahi A, Ablain J. Dis Model Mech 15 dmm049229 (2022)
  147. Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer. Blaquier JB, Cardona AF, Recondo G. Front Oncol 11 787585 (2021)
  148. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. Palma G, Khurshid F, Lu K, Woodward B, Husain H. NPJ Precis Oncol 5 98 (2021)
  149. Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage. Ternet C, Kiel C. Cell Commun Signal 19 31 (2021)
  150. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer. Lee A. Target Oncol 17 727-733 (2022)
  151. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review. Santarpia M, Ciappina G, Spagnolo CC, Squeri A, Passalacqua MI, Aguilar A, Gonzalez-Cao M, Giovannetti E, Silvestris N, Rosell R. Transl Lung Cancer Res 12 346-368 (2023)
  152. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. Cancer Metastasis Rev 40 819-835 (2021)
  153. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients. Kim D, Xue JY, Lito P. Cell 183 850-859 (2020)
  154. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope. Yang H, Zhou X, Fu D, Le C, Wang J, Zhou Q, Liu X, Yuan Y, Ding K, Xiao Q. Cancer Commun (Lond) 43 42-74 (2023)
  155. Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment. Yamamoto K, Iwadate D, Kato H, Nakai Y, Tateishi K, Fujishiro M. Cancers (Basel) 14 4351 (2022)
  156. The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy. Shu CL, Liu YL. Cancer Manag Res 14 3485-3492 (2022)
  157. The Research Progress of Direct KRAS G12C Mutation Inhibitors. Yang A, Li M, Fang M. Pathol Oncol Res 27 631095 (2021)
  158. The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC. Batrash F, Kutmah M, Zhang J. Exp Hematol Oncol 12 93 (2023)
  159. The expanding role for small molecules in immuno-oncology. Offringa R, Kötzner L, Huck B, Urbahns K. Nat Rev Drug Discov 21 821-840 (2022)
  160. Transcription and Translation Inhibitors in Cancer Treatment. Laham-Karam N, Pinto GP, Poso A, Kokkonen P. Front Chem 8 276 (2020)
  161. Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer. O'Sullivan É, Keogh A, Henderson B, Finn SP, Gray SG, Gately K. Cancers (Basel) 15 1635 (2023)
  162. Understand KRAS and the Quest for Anti-Cancer Drugs. Han CW, Jeong MS, Jang SB. Cells 10 842 (2021)
  163. Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer. Koga T, Suda K, Mitsudomi T. Cancer Sci 113 815-827 (2022)
  164. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Li ZN, Zhao L, Yu LF, Wei MJ. Gastroenterol Rep (Oxf) 8 192-205 (2020)
  165. A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer. Grzes M, Oron M, Staszczak Z, Jaiswar A, Nowak-Niezgoda M, Walerych D. Cancers (Basel) 12 (2020)
  166. Achieving the promise and avoiding the peril of chemical probes using genetics. Jones NH, Kapoor TM. Curr Opin Struct Biol 81 102628 (2023)
  167. Adaptive chromatin remodeling and transcriptional changes of the functional kinome in tumor cells in response to targeted kinase inhibition. East MP, Johnson GL. J Biol Chem 298 101525 (2022)
  168. Adjuvant Chemotherapy for Stage III Colon Cancer. Taieb J, Gallois C. Cancers (Basel) 12 (2020)
  169. Antibody-Based Approaches to Target Pancreatic Tumours. Sorbara M, Cordelier P, Bery N. Antibodies (Basel) 11 47 (2022)
  170. Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. Gillson J, Abd El-Aziz YS, Leck LYW, Jansson PJ, Pavlakis N, Samra JS, Mittal A, Sahni S. Cancers (Basel) 14 3528 (2022)
  171. Avancées dans la prise en charge de l’adénocarcinome canalaire pancréatique. O'Kane GM, Ladak F, Gallinger S. CMAJ 193 E1362-E1370 (2021)
  172. Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. Johnson RL, Cummings M, Thangavelu A, Theophilou G, de Jong D, Orsi NM. Cancers (Basel) 13 6231 (2021)
  173. Biological and Translational Considerations regarding the Recent Therapeutic Successes and Upcoming Challenges for Multiple Myeloma. Mitsiades CS. Cold Spring Harb Perspect Med 11 a034900 (2021)
  174. Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors. Jiang S, Geng S, Luo X, Zhang C, Yu Y, Cheng M, Zhang S, Shi N, Dong M. Front Immunol 13 995785 (2022)
  175. Biomedical Applications of Non-Small Cell Lung Cancer Spheroids. Rozenberg JM, Filkov GI, Trofimenko AV, Karpulevich EA, Parshin VD, Royuk VV, Sekacheva MI, Durymanov MO. Front Oncol 11 791069 (2021)
  176. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Aizer AA, Lamba N, Ahluwalia MS, Aldape K, Boire A, Brastianos PK, Brown PD, Camidge DR, Chiang VL, Davies MA, Hu LS, Huang RY, Kaufmann T, Kumthekar P, Lam K, Lee EQ, Lin NU, Mehta M, Parsons M, Reardon DA, Sheehan J, Soffietti R, Tawbi H, Weller M, Wen PY. Neuro Oncol 24 1613-1646 (2022)
  177. Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities. Wang Y, Lakoma A, Zogopoulos G. Genes (Basel) 11 (2020)
  178. Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions. Watterson A, Coelho MA. Cell Commun Signal 21 45 (2023)
  179. Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma. Topham JT, Renouf DJ, Schaeffer DF. Ther Adv Med Oncol 15 17588359231157651 (2023)
  180. Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer. Lee JJ, Jain V, Amaravadi RK. Int J Mol Sci 22 12402 (2021)
  181. Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm. Raut P, Nimmakayala RK, Batra SK, Ponnusamy MP. Biochim Biophys Acta Rev Cancer 1878 188851 (2023)
  182. Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. Rachiglio AM, Sacco A, Forgione L, Esposito C, Chicchinelli N, Normanno N. Explor Target Antitumor Ther 1 53-70 (2020)
  183. Colorectal cancer-derived exosomes and modulation KRAS signaling. Wan YH, Liu QS, Wan SS, Wang RW. Clin Transl Oncol 24 2074-2080 (2022)
  184. Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Janssen E, Subtil B, de la Jara Ortiz F, Verheul HMW, Tauriello DVF. Cancers (Basel) 12 (2020)
  185. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Baraibar I, Mirallas O, Saoudi N, Ros J, Salvà F, Tabernero J, Élez E. Cancers (Basel) 13 6311 (2021)
  186. Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead. Li HY, Qi WL, Wang YX, Meng LH. Genes Dis 10 403-414 (2023)
  187. Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. Martin C, Enrico D. Front Oncol 12 962947 (2022)
  188. Current therapy and development of therapeutic agents for lung cancer. Wang Z, Kim J, Zhang P, Galvan Achi JM, Jiang Y, Rong L. Cell Insight 1 100015 (2022)
  189. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A. Gut 70 606-617 (2021)
  190. Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner. Bontoux C, Hofman V, Brest P, Ilié M, Mograbi B, Hofman P. Cancers (Basel) 14 1628 (2022)
  191. Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways. Bararia A, Das A, Mitra S, Banerjee S, Chatterjee A, Sikdar N. World J Gastrointest Oncol 15 1505-1519 (2023)
  192. Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. Danesi R, Fogli S, Indraccolo S, Del Re M, Dei Tos AP, Leoncini L, Antonuzzo L, Bonanno L, Guarneri V, Pierini A, Amunni G, Conte P. ESMO Open 6 100040 (2021)
  193. Early stage gastric adenocarcinoma: clinical and molecular landscapes. Hirata Y, Noorani A, Song S, Wang L, Ajani JA. Nat Rev Clin Oncol 20 453-469 (2023)
  194. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer. Lu Y, Yang Y, Zhu G, Zeng H, Fan Y, Guo F, Xu D, Wang B, Chen D, Ge G. Int J Biol Sci 19 3360-3382 (2023)
  195. Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma. Roalsø MTT, Hald ØH, Alexeeva M, Søreide K. Cancers (Basel) 14 546 (2022)
  196. Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma. Rudloff U. Expert Opin Emerg Drugs 27 345-368 (2022)
  197. Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer. Pan K, Concannon K, Li J, Zhang J, Heymach JV, Le X. Nat Rev Clin Oncol 20 716-732 (2023)
  198. Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside. Burska AN, Ilyassova B, Dildabek A, Khamijan M, Begimbetova D, Molnár F, Sarbassov DD. Cells 11 3454 (2022)
  199. Epigenetic regulation in lung cancer. Ramazi S, Daddzadi M, Sahafnejad Z, Allahverdi A. MedComm (2020) 4 e401 (2023)
  200. Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers. Adachi Y, Kimura R, Hirade K, Ebi H. Cancers (Basel) 13 5081 (2021)
  201. Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening. Hou J, He Z, Liu T, Chen D, Wang B, Wen Q, Zheng X. Front Oncol 12 755053 (2022)
  202. Exploiting the molecular subtypes and genetic landscape in pancreatic cancer: the quest to find effective drugs. Elebo N, Abdel-Shafy EA, Cacciatore S, Nweke EE. Front Genet 14 1170571 (2023)
  203. FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022. Rizzo C, Amata S, Pibiri I, Pace A, Buscemi S, Palumbo Piccionello A. Int J Mol Sci 24 7728 (2023)
  204. FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect. Hossain M, Habib I, Singha K, Kumar A. Heliyon 10 e23172 (2024)
  205. Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs. Chandra G, Singh DV, Mahato GK, Patel S. Chem Zvesti 1-22 (2023)
  206. From Retrograde Menstruation to Endometrial Determinism and a Brave New World of "Root Treatment" of Endometriosis: Destiny or a Fanciful Utopia? Guo SW, Habiba M, Benagiano G. Biomolecules 13 336 (2023)
  207. From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Chen Y, Liu QP, Xie H, Ding J. Acta Pharmacol Sin (2023)
  208. Future perspectives from lung cancer pre-clinical models: new treatments are coming? Bersani F, Morena D, Picca F, Morotti A, Tabbò F, Bironzo P, Righi L, Taulli R. Transl Lung Cancer Res 9 2629-2644 (2020)
  209. Genetic analysis in the clinical management of biliary tract cancer. Wakai T, Nagahashi M, Shimada Y, Prasoon P, Sakata J. Ann Gastroenterol Surg 4 316-323 (2020)
  210. Genomics-guided pre-clinical development of cancer therapies. Francies HE, McDermott U, Garnett MJ. Nat Cancer 1 482-492 (2020)
  211. Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Golan T, Casolino R, Biankin AV, Hammel P, Whitaker KD, Hall MJ, Riegert-Johnson DL. Ther Adv Med Oncol 15 17588359231189127 (2023)
  212. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. Marmorino F, Boccaccino A, Germani MM, Falcone A, Cremolini C. Cancers (Basel) 12 (2020)
  213. Immune regulation in gastric adenocarcinoma is linked with therapeutic efficacy and improved recovery. Xu Z, Lin X, Zeng H, Ma X, Nabi G, Abidin ZU, Wang L, Wang L. Front Genet 14 1238248 (2023)
  214. Immune vulnerabilities of mutant KRAS in pancreatic cancer. Cheng NC, Vonderheide RH. Trends Cancer 9 928-936 (2023)
  215. Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era? Matteucci L, Bittoni A, Gallo G, Ridolfi L, Passardi A. Cancers (Basel) 15 5189 (2023)
  216. Immunotherapy and Pancreatic Cancer: A Lost Challenge? Laface C, Memeo R, Maselli FM, Santoro AN, Iaia ML, Ambrogio F, Laterza M, Cazzato G, Guarini C, De Santis P, Perrone M, Fedele P. Life (Basel) 13 1482 (2023)
  217. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Zhu Z, McGray AJR, Jiang W, Lu B, Kalinski P, Guo ZS. Mol Cancer 21 196 (2022)
  218. K-RAS4A: Lead or Supporting Role in Cancer Biology? Aran V. Front Mol Biosci 8 729830 (2021)
  219. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? Bannoura SF, Khan HY, Azmi AS. Front Oncol 12 1013902 (2022)
  220. KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration. Yang Y, Zhang H, Huang S, Chu Q. J Clin Med 12 709 (2023)
  221. KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block. Garcia-Robledo JE, Rosell R, Ruíz-Patiño A, Sotelo C, Arrieta O, Zatarain-Barrón L, Ordoñez C, Jaller E, Rojas L, Russo A, de Miguel-Pérez D, Rolfo C, Cardona AF. Ther Adv Respir Dis 16 17534666211066064 (2022)
  222. KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications. Pereira F, Ferreira A, Reis CA, Sousa MJ, Oliveira MJ, Preto A. Cells 11 398 (2022)
  223. KRAS inhibition in metastatic colorectal cancer: An update. Nusrat M, Yaeger R. Curr Opin Pharmacol 68 102343 (2023)
  224. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. Gurreri E, Genovese G, Perelli L, Agostini A, Piro G, Carbone C, Tortora G. Int J Mol Sci 24 9313 (2023)
  225. KRAS: A Druggable Target in Colon Cancer Patients. Negri F, Bottarelli L, de'Angelis GL, Gnetti L. Int J Mol Sci 23 4120 (2022)
  226. Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer. Gao L, Shen W. Front Genet 13 890247 (2022)
  227. Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer. Buszka K, Ntzifa A, Owecka B, Kamińska P, Kolecka-Bednarczyk A, Zabel M, Nowicki M, Lianidou E, Budna-Tukan J. Cells 11 2871 (2022)
  228. LncRNA MALAT1 signaling pathway and clinical applications in overcome on cancers metastasis. Mazarei M, Shahabi Rabori V, Ghasemi N, Salehi M, Rayatpisheh N, Jahangiri N, Saberiyan M. Clin Exp Med (2023)
  229. Mechanisms of Resistance to KRASG12C Inhibitors. Dunnett-Kane V, Nicola P, Blackhall F, Lindsay C. Cancers (Basel) 13 (2021)
  230. Medicinal chemistry perspective of pyrido[2,3-d]pyrimidines as anticancer agents. Kumar A, Bhagat KK, Singh AK, Singh H, Angre T, Verma A, Khalilullah H, Jaremko M, Jaremko M, Emwas AH, Kumar P. RSC Adv 13 6872-6908 (2023)
  231. Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer. DeNicola GM, Shackelford DB. Cold Spring Harb Perspect Med 11 a037838 (2021)
  232. Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy. Mazzaschi G, Leonetti A, Minari R, Gnetti L, Quaini F, Tiseo M, Facchinetti F. Curr Treat Options Oncol 22 96 (2021)
  233. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE. Int J Mol Sci 22 (2020)
  234. Molecular aspects of pancreatic cancer: focus on reprogrammed metabolism in a nutrient-deficient environment and potential therapeutic targets. Słotwiński R, Lech G, Słotwińska SM. Cent Eur J Immunol 46 258-263 (2021)
  235. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Wang Z, Xing Y, Li B, Li X, Liu B, Wang Y. Mol Biomed 3 42 (2022)
  236. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Martini G, Dienstmann R, Ros J, Baraibar I, Cuadra-Urteaga JL, Salva F, Ciardiello D, Mulet N, Argiles G, Tabernero J, Elez E. Ther Adv Med Oncol 12 1758835920936089 (2020)
  237. Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors. Zhou X, Ji Y, Zhou J. Molecules 28 3615 (2023)
  238. Nanotechnology - a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer. Gorachinov F, Mraiche F, Moustafa DA, Hishari O, Ismail Y, Joseph J, Crcarevska MS, Dodov MG, Geskovski N, Goracinova K. Beilstein J Nanotechnol 14 240-261 (2023)
  239. Natural Products Attenuating Biosynthesis, Processing, and Activity of Ras Oncoproteins: State of the Art and Future Perspectives. Tisi R, Gaponenko V, Vanoni M, Sacco E. Biomolecules 10 (2020)
  240. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2. Olmedo ME, Cervera R, Cabezon-Gutierrez L, Lage Y, Corral de la Fuente E, Gómez Rueda A, Mielgo-Rubio X, Trujillo JC, Couñago F. World J Clin Oncol 13 276-286 (2022)
  241. Non-Coding RNAs in Lung Tumor Initiation and Progression. Santos RM, Moreno C, Zhang WC. Int J Mol Sci 21 (2020)
  242. Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit. Ning W, Marti TM, Dorn P, Peng RW. Front Oncol 12 1004669 (2022)
  243. Notch Transduction in Non-Small Cell Lung Cancer. Sharif A, Shaji A, Chammaa M, Pawlik E, Fernandez-Valdivia R. Int J Mol Sci 21 (2020)
  244. Orchestration of mesenchymal plasticity and immune evasiveness via rewiring of the metabolic program in pancreatic ductal adenocarcinoma. Hashimoto A, Handa H, Hata S, Hashimoto S. Front Oncol 12 1005566 (2022)
  245. Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. Ettrich TJ, Sturm N, Güthle M, Hüttner FJ, Perkhofer L. Visc Med 38 20-29 (2022)
  246. Peptides That Block RAS-p21 Protein-Induced Cell Transformation. Pincus MR, Lin B, Patel P, Gabutan E, Zohar N, Bowne WB. Biomedicines 11 471 (2023)
  247. Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer. Sato M. Oncol Lett 19 3617-3626 (2020)
  248. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Nagayama S, Low SK, Kiyotani K, Nakamura Y. Cancers (Basel) 13 4803 (2021)
  249. Precision Therapy of Pancreatic Cancer: From Bench to Bedside. Ciecielski KJ, Berninger A, Algül H. Visc Med 36 373-380 (2020)
  250. Precision medicine for metastatic colorectal cancer in clinical practice. Riedesser JE, Ebert MP, Betge J. Ther Adv Med Oncol 14 17588359211072703 (2022)
  251. Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy. Verbanac D, Čeri A, Hlapčić I, Shakibaei M, Brockmueller A, Krušlin B, Ljubičić N, Baršić N, Detel D, Batičić L, Rumora L, Somborac-Bačura A, Štefanović M, Ćelap I, Demirović A, Petlevski R, Petrik J, Grdić Rajković M, Hulina-Tomašković A, Rako I, Saso L, Barišić K. Int J Mol Sci 22 4327 (2021)
  252. Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Wankhede D, Bontoux C, Grover S, Hofman P. Diagnostics (Basel) 13 3043 (2023)
  253. RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming. Miller-Phillips L, Collisson EA. Curr Treat Options Oncol 24 1088-1101 (2023)
  254. RAS degraders: The new frontier for RAS-driven cancers. Escher TE, Satchell KJF. Mol Ther 31 1904-1919 (2023)
  255. Ras Isoforms from Lab Benches to Lives-What Are We Missing and How Far Are We? Nair A, Kubatzky KF, Saha B. Int J Mol Sci 22 6508 (2021)
  256. Recent Advances in Understanding Biological GTP Hydrolysis through Molecular Simulation. Calixto AR, Moreira C, Kamerlin SCL. ACS Omega 5 4380-4385 (2020)
  257. Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy. Tatli O, Dinler Doganay G. Molecules 26 7561 (2021)
  258. Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials. Xie X, Yu T, Li X, Zhang N, Foster LJ, Peng C, Huang W, He G. Signal Transduct Target Ther 8 335 (2023)
  259. Recent advances in understanding pancreatic cancer. Stott MC, Oldfield L, Hale J, Costello E, Halloran CM. Fac Rev 11 9 (2022)
  260. Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade. Sinha D, Moseley P, Lu X, Wright Q, Gabrielli B, Frazer IH, Cruz JLG. Cancers (Basel) 14 6150 (2022)
  261. Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer. Di Federico A, Ricciotti I, Favorito V, Michelina SV, Scaparone P, Metro G, De Giglio A, Pecci F, Lamberti G, Ambrogio C, Ricciuti B. Curr Oncol Rep (2023)
  262. Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. Tang YL, Li DD, Duan JY, Sheng LM, Wang X. World J Gastroenterol 29 926-948 (2023)
  263. Role of RUNX3 in Restriction Point Regulation. Lee JW, Lee YS, Kim MK, Chi XZ, Kim D, Bae SC. Cells 12 708 (2023)
  264. Small molecular inhibitors for KRAS-mutant cancers. Wu X, Song W, Cheng C, Liu Z, Li X, Cui Y, Gao Y, Li D. Front Immunol 14 1223433 (2023)
  265. Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers. Hyun S, Shin D. Int J Mol Sci 22 12142 (2021)
  266. Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies. Shetu SA, Bandyopadhyay D. Int J Mol Sci 23 3706 (2022)
  267. Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer. Zhang SS, Nagasaka M. Lung Cancer (Auckl) 12 115-122 (2021)
  268. Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer. Kano Y, Suenaga M, Uetake H. Curr Oncol 30 6546-6558 (2023)
  269. Synthetic Vulnerabilities in the KRAS Pathway. Roman M, Hwang E, Sweet-Cordero EA. Cancers (Basel) 14 2837 (2022)
  270. Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. Lellouche L, Palmieri LJ, Dermine S, Brezault C, Chaussade S, Coriat R. Ther Adv Med Oncol 13 17588359211018539 (2021)
  271. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. Kung HC, Yu J. MedComm (2020) 4 e216 (2023)
  272. Targeting KRAS G12C mutations in colorectal cancer. Zhao MH, Wu AW. Gastroenterol Rep (Oxf) 11 goac083 (2023)
  273. Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. Uras IZ, Moll HP, Casanova E. Int J Mol Sci 21 (2020)
  274. Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies. Désage AL, Léonce C, Swalduz A, Ortiz-Cuaran S. Front Oncol 12 796832 (2022)
  275. Targeting KRAS: Crossroads of Signaling and Immune Inhibition. Kato S, Fujiwara Y, Hong DS. J Immunother Precis Oncol 5 68-78 (2022)
  276. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities. Wang P, Laster K, Jia X, Dong Z, Liu K. Mol Cancer 22 208 (2023)
  277. Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectives. Toulany M. Clin Transl Radiat Oncol 38 6-14 (2023)
  278. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review). Zhang J, Darman L, Hassan MS, Von Holzen U, Awasthi N. Oncol Rep 50 206 (2023)
  279. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review. Bteich F, Mohammadi M, Li T, Bhat MA, Sofianidi A, Wei N, Kuang C. Int J Mol Sci 24 12030 (2023)
  280. Targeting KRAS in Non-Small Cell Lung Cancer. Corral de la Fuente E, Olmedo Garcia ME, Gomez Rueda A, Lage Y, Garrido P. Front Oncol 11 792635 (2021)
  281. Targeting KRAS in Pancreatic Cancer. Cowzer D, Zameer M, Conroy M, Kolch W, Duffy AG. J Pers Med 12 1870 (2022)
  282. Targeting KRAS mutant lung cancer: light at the end of the tunnel. Drosten M, Barbacid M. Mol Oncol 16 1057-1071 (2022)
  283. Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies. Caughey BA, Strickler JH. Drugs 84 27-44 (2024)
  284. Targeting KRASG12C in colorectal cancer: the beginning of a new era. Ciardiello D, Maiorano BA, Martinelli E. ESMO Open 8 100745 (2022)
  285. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun. Bungaro M, Novello S, Passiglia F. Curr Treat Options Oncol 23 1699-1720 (2022)
  286. Targeting Mutant KRAS in Pancreatic Cancer: Futile or Promising? Nollmann FI, Ruess DA. Biomedicines 8 (2020)
  287. Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives. Li JX, Li RZ, Ma LR, Wang P, Xu DH, Huang J, Li LQ, Tang L, Xie Y, Leung EL, Yan PY. Front Pharmacol 13 875330 (2022)
  288. Targeting Mutated KRAS Genes to Treat Solid Tumours. Krishnan T, Roberts-Thomson R, Broadbridge V, Price T. Mol Diagn Ther 26 39-49 (2022)
  289. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials. Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Genes Dis 10 76-88 (2023)
  290. Targeting Ras with protein engineering. Tomazini A, Shifman JM. Oncotarget 14 672-687 (2023)
  291. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Petroni G, Buqué A, Coussens LM, Galluzzi L. Nat Rev Drug Discov 21 440-462 (2022)
  292. Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS. Yin G, Huang J, Petela J, Jiang H, Zhang Y, Gong S, Wu J, Liu B, Shi J, Gao Y. Signal Transduct Target Ther 8 212 (2023)
  293. The Advance and Correlation of KRAS Mutation With the Fertility-Preservation Treatment of Endometrial Cancer in the Background of Molecular Classification Application. Yu K, Wang Y. Pathol Oncol Res 27 1609906 (2021)
  294. The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine. Wang Q, Han J, Sorochinsky A, Landa A, Butler G, Soloshonok VA. Pharmaceuticals (Basel) 15 999 (2022)
  295. The Next Generation of KRAS Targeting: Reasons for Excitement and Concern. Akhave NS, Biter AB, Hong DS. Mol Cancer Ther 21 1645-1651 (2022)
  296. The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets. Rocca A, Braga L, Volpe MC, Maiocchi S, Generali D. Cancers (Basel) 14 5306 (2022)
  297. The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures. Ferrara MG, Stefani A, Pilotto S, Carbone C, Vita E, Di Salvatore M, D'Argento E, Sparagna I, Monaca F, Valente G, Vitale A, Piro G, Belluomini L, Milella M, Tortora G, Bria E. Front Oncol 11 792385 (2021)
  298. The Role and Therapeutic Implications of Inflammation in the Pathogenesis of Brain Arteriovenous Malformations. Ricciardelli AR, Robledo A, Fish JE, Kan PT, Harris TH, Wythe JD. Biomedicines 11 2876 (2023)
  299. The Role of EREG/EGFR Pathway in Tumor Progression. Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N, Luo CS, Wu SM. Int J Mol Sci 22 12828 (2021)
  300. The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers. Tria SM, Burge ME, Whitehall VLJ. Cancers (Basel) 15 2375 (2023)
  301. The current state of the art and future trends in RAS-targeted cancer therapies. Punekar SR, Velcheti V, Neel BG, Wong KK. Nat Rev Clin Oncol 19 637-655 (2022)
  302. The emerging role of mass spectrometry-based proteomics in drug discovery. Meissner F, Geddes-McAlister J, Mann M, Bantscheff M. Nat Rev Drug Discov (2022)
  303. The genetic profile and molecular subtypes of human pseudomyxoma peritonei and appendiceal mucinous neoplasms: a systematic review. Murage NW, Ahmed NM, Underwood TJ, Walters ZS, Breininger SP. Cancer Metastasis Rev 42 335-359 (2023)
  304. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. Cell Rep Med 2 100186 (2021)
  305. The path to the clinic: a comprehensive review on direct KRASG12C inhibitors. Kwan AK, Piazza GA, Keeton AB, Leite CA. J Exp Clin Cancer Res 41 27 (2022)
  306. The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma. Evan T, Wang VM, Behrens A. Oncogene 41 4686-4695 (2022)
  307. The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review. Spagnuolo A, Maione P, Gridelli C. Transl Lung Cancer Res 11 1199-1216 (2022)
  308. Therapeutic Targets of KRAS in Colorectal Cancer. Rahman S, Garrel S, Gerber M, Maitra R, Goel S. Cancers (Basel) 13 6233 (2021)
  309. Translational advances in pancreatic ductal adenocarcinoma therapy. Hosein AN, Dougan SK, Aguirre AJ, Maitra A. Nat Cancer 3 272-286 (2022)
  310. Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. Kim SI, Cassella CR, Byrne KT. Front Immunol 11 629722 (2020)
  311. Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Kato S. Diagnostics (Basel) 11 252 (2021)
  312. UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect. Caggiano EG, Taniguchi CM. Cancer Metastasis Rev (2024)
  313. Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies. Malik P, Rani R, Solanki R, Patel VH, Mukherjee TK. Explor Target Antitumor Ther 4 850-895 (2023)
  314. Update on Targeted Therapy in Medullary Thyroid Cancer. Okafor C, Hogan J, Raygada M, Thomas BJ, Akshintala S, Glod JW, Del Rivero J. Front Endocrinol (Lausanne) 12 708949 (2021)
  315. Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI. Volovat SR, Augustin I, Zob D, Boboc D, Amurariti F, Volovat C, Stefanescu C, Stolniceanu CR, Ciocoiu M, Dumitras EA, Danciu M, Apostol DGC, Drug V, Shurbaji SA, Coca LG, Leon F, Iftene A, Herghelegiu PC. Cancers (Basel) 14 4834 (2022)
  316. [Medicinal treatment of pancreatic cancer : Still a domain of chemotherapy?] Feldmann G. Internist (Berl) 61 226-232 (2020)

Articles citing this publication (440)

  1. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, Kato T, Curioni-Fontecedro A, Sacher A, Spira A, Ramalingam SS, Takahashi T, Besse B, Anderson A, Ang A, Tran Q, Mather O, Henary H, Ngarmchamnanrith G, Friberg G, Velcheti V, Govindan R. N Engl J Med 384 2371-2381 (2021)
  2. Bispecific antibodies targeting mutant RAS neoantigens. Douglass J, Hsiue EH, Mog BJ, Hwang MS, DiNapoli SR, Pearlman AH, Miller MS, Wright KM, Azurmendi PA, Wang Q, Paul S, Schaefer A, Skora AD, Molin MD, Konig MF, Liu Q, Watson E, Li Y, Murphy MB, Pardoll DM, Bettegowda C, Papadopoulos N, Gabelli SB, Kinzler KW, Vogelstein B, Zhou S. Sci Immunol 6 eabd5515 (2021)
  3. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Fujii Y, Sato Y, Suzuki H, Kakiuchi N, Yoshizato T, Lenis AT, Maekawa S, Yokoyama A, Takeuchi Y, Inoue Y, Ochi Y, Shiozawa Y, Aoki K, Yoshida K, Kataoka K, Nakagawa MM, Nannya Y, Makishima H, Miyakawa J, Kawai T, Morikawa T, Shiraishi Y, Chiba K, Tanaka H, Nagae G, Sanada M, Sugihara E, Sato TA, Nakagawa T, Fukayama M, Ushiku T, Aburatani H, Miyano S, Coleman JA, Homma Y, Solit DB, Kume H, Ogawa S. Cancer Cell 39 793-809.e8 (2021)
  4. KRAS drives immune evasion in a genetic model of pancreatic cancer. Ischenko I, D'Amico S, Rao M, Li J, Hayman MJ, Powers S, Powers S, Petrenko O, Reich NC. Nat Commun 12 1482 (2021)
  5. GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf. Zhang Z, Gao R, Hu Q, Peacock H, Peacock DM, Dai S, Shokat KM, Suga H. ACS Cent Sci 6 1753-1761 (2020)
  6. Cell Type-specific Adaptive Signaling Responses to KRASG12C Inhibition. Solanki HS, Welsh EA, Fang B, Izumi V, Darville L, Stone B, Franzese R, Chavan S, Kinose F, Imbody D, Koomen JM, Rix U, Haura EB. Clin Cancer Res 27 2533-2548 (2021)
  7. Editorial The KRAS-G12C inhibitor: activity and resistance. Liu J, Kang R, Tang D. Cancer Gene Ther 29 875-878 (2022)
  8. The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Briere DM, Li S, Calinisan A, Sudhakar N, Aranda R, Hargis L, Peng DH, Deng J, Engstrom LD, Hallin J, Gatto S, Fernandez-Banet J, Pavlicek A, Wong KK, Christensen JG, Olson P. Mol Cancer Ther 20 975-985 (2021)
  9. An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants. Zafra MP, Parsons MJ, Kim J, Alonso-Curbelo D, Goswami S, Schatoff EM, Han T, Katti A, Fernandez MTC, Wilkinson JE, Piskounova E, Dow LE. Cancer Discov 10 1654-1671 (2020)
  10. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer. Brown WS, McDonald PC, Nemirovsky O, Awrey S, Chafe SC, Schaeffer DF, Li J, Renouf DJ, Stanger BZ, Dedhar S. Cell Rep Med 1 100131 (2020)
  11. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling. Ponsioen B, Post JB, Buissant des Amorie JR, Laskaris D, van Ineveld RL, Kersten S, Bertotti A, Sassi F, Sipieter F, Cappe B, Mertens S, Verlaan-Klink I, Boj SF, Vries RGJ, Rehmann H, Vandenabeele P, Riquet FB, Trusolino L, Bos JL, Snippert HJG. Nat Cell Biol 23 377-390 (2021)
  12. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Wang Z, Hausmann S, Lyu R, Li TM, Lofgren SM, Flores NM, Fuentes ME, Caporicci M, Yang Z, Meiners MJ, Cheek MA, Howard SA, Zhang L, Elias JE, Kim MP, Maitra A, Wang H, Bassik MC, Keogh MC, Sage J, Gozani O, Mazur PK. Cancer Cell 37 834-849.e13 (2020)
  13. Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene Signature. Liu LW, Hsieh YY, Yang PM. J Pers Med 10 E130 (2020)
  14. Mechanistic insights into the effect of phosphorylation on Ras conformational dynamics and its interactions with cell signaling proteins. Wang Y, Ji D, Lei C, Chen Y, Qiu Y, Li X, Li M, Ni D, Pu J, Zhang J, Fu Q, Liu Y, Lu S. Comput Struct Biotechnol J 19 1184-1199 (2021)
  15. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. Zhang Z, Rohweder PJ, Ongpipattanakul C, Basu K, Bohn MF, Dugan EJ, Steri V, Hann B, Shokat KM, Craik CS. Cancer Cell 40 1060-1069.e7 (2022)
  16. Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy. Ni D, Wei J, He X, Rehman AU, Li X, Qiu Y, Pu J, Lu S, Zhang J. Chem Sci 12 464-476 (2020)
  17. Comment Small molecule combats cancer-causing KRAS protein at last. Herbst RS, Schlessinger J. Nature 575 294-295 (2019)
  18. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y, Liu M, Pang X. J Clin Invest 130 1752-1766 (2020)
  19. 10 years into the resurgence of covalent drugs. De Vita E. Future Med Chem 13 193-210 (2021)
  20. An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. Zaidman D, Gehrtz P, Filep M, Fearon D, Gabizon R, Douangamath A, Prilusky J, Duberstein S, Cohen G, Owen CD, Resnick E, Strain-Damerell C, Lukacik P, Covid-Moonshot Consortium, Barr H, Walsh MA, von Delft F, London N. Cell Chem Biol 28 1795-1806.e5 (2021)
  21. Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States. Lim S, Khoo R, Juang YC, Gopal P, Zhang H, Yeo C, Peh KM, Teo J, Ng S, Henry B, Partridge AW. ACS Cent Sci 7 274-291 (2021)
  22. Genetic Ancestry Contributes to Somatic Mutations in Lung Cancers from Admixed Latin American Populations. Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorner AR, Nag A, Watson J, Genovese G, Rodriguez J, Gelbard MK, Corrales-Rodriguez L, Mitsuishi Y, Ha G, Campbell JD, Oxnard GR, Arrieta O, Cardona AF, Gusev A, Meyerson M. Cancer Discov 11 591-598 (2021)
  23. Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases. da Silva EM, Fix DJ, Sebastiao APM, Selenica P, Ferrando L, Kim SH, Stylianou A, Da Cruz Paula A, Pareja F, Smith ES, Zehir A, Konner JA, Cadoo K, Reis-Filho JS, Abu-Rustum NR, Mueller JJ, Weigelt B, Park KJ. Mod Pathol 34 1570-1587 (2021)
  24. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. J Immunother Cancer 9 e002891 (2021)
  25. Sticking it to KRAS: Covalent Inhibitors Enter the Clinic. McCormick F. Cancer Cell 37 3-4 (2020)
  26. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer. Arbour KC, Rizvi H, Plodkowski AJ, Hellmann MD, Knezevic A, Heller G, Yu HA, Ladanyi M, Kris MG, Arcila ME, Rudin CM, Lito P, Riely GJ. Clin Cancer Res 27 2209-2215 (2021)
  27. Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication. Qiu Y, Yin X, Li X, Wang Y, Fu Q, Huang R, Lu S. Pharmaceutics 13 747 (2021)
  28. A KRAS-responsive long non-coding RNA controls microRNA processing. Shi L, Magee P, Fassan M, Sahoo S, Leong HS, Lee D, Sellers R, Brullé-Soumaré L, Cairo S, Monteverde T, Volinia S, Smith DD, Di Leva G, Galuppini F, Paliouras AR, Zeng K, O'Keefe R, Garofalo M. Nat Commun 12 2038 (2021)
  29. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. N Engl J Med 383 1207-1217 (2020)
  30. Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis. Khan I, Marelia-Bennet C, Lefler J, Zuberi M, Denbaum E, Koide A, Connor DM, Broome AM, Pécot T, Timmers C, Ostrowski MC, Koide S, O'Bryan JP. Small GTPases 13 114-127 (2022)
  31. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS. Li C, Vides A, Kim D, Xue JY, Zhao Y, Lito P. Science 374 197-201 (2021)
  32. KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. Jones GD, Caso R, Tan KS, Mastrogiacomo B, Sanchez-Vega F, Liu Y, Connolly JG, Murciano-Goroff YR, Bott MJ, Adusumilli PS, Molena D, Rocco G, Rusch VW, Sihag S, Misale S, Yaeger R, Drilon A, Arbour KC, Riely GJ, Rosen N, Lito P, Zhang H, Lyden DC, Rudin CM, Jones DR, Li BT, Isbell JM. Clin Cancer Res 27 2604-2612 (2021)
  33. ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. Remsberg JR, Suciu RM, Zambetti NA, Hanigan TW, Firestone AJ, Inguva A, Long A, Ngo N, Lum KM, Henry CL, Richardson SK, Predovic M, Huang B, Dix MM, Howell AR, Niphakis MJ, Shannon K, Cravatt BF. Nat Chem Biol 17 856-864 (2021)
  34. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Kemp SB, Cheng N, Markosyan N, Sor R, Kim IK, Hallin J, Shoush J, Quinones L, Brown NV, Bassett JB, Joshi N, Yuan S, Smith M, Vostrejs WP, Perez-Vale KZ, Kahn B, Mo F, Donahue TR, Radu CG, Clendenin C, Christensen JG, Vonderheide RH, Stanger BZ. Cancer Discov 13 298-311 (2023)
  35. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Loong HH, Du N, Cheng C, Lin H, Guo J, Lin G, Li M, Jiang T, Shi Z, Cui Y, Jin X, Yao J, Xing Y, Yao M, Wang K, Mok TSK, Liu L. Transl Lung Cancer Res 9 1759-1769 (2020)
  36. KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma. Frost N, Kollmeier J, Vollbrecht C, Grah C, Matthes B, Pultermann D, von Laffert M, Lüders H, Olive E, Raspe M, Mairinger T, Ochsenreither S, Blum T, Hummel M, Suttorp N, Witzenrath M, Grohé C. Transl Lung Cancer Res 10 737-752 (2021)
  37. Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Teng KW, Tsai ST, Hattori T, Fedele C, Koide A, Yang C, Hou X, Zhang Y, Neel BG, O'Bryan JP, Koide S. Nat Commun 12 2656 (2021)
  38. A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer. Milton CK, Self AJ, Clarke PA, Banerji U, Piccioni F, Root DE, Whittaker SR. Mol Cancer Ther 19 1423-1435 (2020)
  39. An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth. Vidimar V, Beilhartz GL, Park M, Biancucci M, Kieffer MB, Gius DR, Melnyk RA, Satchell KJF. Proc Natl Acad Sci U S A 117 16938-16948 (2020)
  40. Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. Li YC, Lytle NK, Gammon ST, Wang L, Hayes TK, Sutton MN, Bast RC, Der CJ, Piwnica-Worms D, McCormick F, Wahl GM. Proc Natl Acad Sci U S A 117 12121-12130 (2020)
  41. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Botrus G, Kosirorek H, Sonbol MB, Kusne Y, Uson Junior PLS, Borad MJ, Ahn DH, Kasi PM, Drusbosky LM, Dada H, Surapaneni PK, Starr J, Ritter A, McMillan J, Wylie N, Mody K, Bekaii-Saab TS. Oncologist 26 569-578 (2021)
  42. A Sos proteomimetic as a pan-Ras inhibitor. Hong SH, Yoo DY, Conway L, Richards-Corke KC, Parker CG, Arora PS. Proc Natl Acad Sci U S A 118 e2101027118 (2021)
  43. Biological significance of KRAS mutant allele expression in ovarian endometriosis. Yachida N, Yoshihara K, Suda K, Nakaoka H, Ueda H, Sugino K, Yamaguchi M, Mori Y, Yamawaki K, Tamura R, Ishiguro T, Kase H, Motoyama T, Enomoto T. Cancer Sci 112 2020-2032 (2021)
  44. Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. Tang KH, Li S, Khodadadi-Jamayran A, Jen J, Han H, Guidry K, Chen T, Hao Y, Fedele C, Zebala JA, Maeda DY, Christensen JG, Olson P, Athanas A, Loomis CA, Tsirigos A, Wong KK, Neel BG. Cancer Discov 12 47-61 (2022)
  45. Conformations and binding pockets of HRas and its guanine nucleotide exchange factors complexes in the guanosine triphosphate exchange process. Xiong Y, Zeng J, Xia F, Cui Q, Deng X, Xu X. J Comput Chem 43 906-916 (2022)
  46. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, Da Cruz Paula AF, Saiki AY, Mohn D, Achanta P, Sisk AE, Arora KS, Roy RS, Kim D, Li C, Lim LP, Li M, Bahr A, Loomis BR, de Stanchina E, Reis-Filho JS, Weigelt B, Berger M, Riely G, Arbour KC, Lipford JR, Li BT, Lito P. Nature 599 679-683 (2021)
  47. Elevated FSP1 protects KRAS-mutated cells from ferroptosis during tumor initiation. Müller F, Lim JKM, Bebber CM, Seidel E, Tishina S, Dahlhaus A, Stroh J, Beck J, Yapici FI, Nakayama K, Torres Fernández L, Brägelmann J, Leprivier G, von Karstedt S. Cell Death Differ 30 442-456 (2023)
  48. Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer. Yu C, Luo D, Yu J, Zhang M, Zheng X, Xu G, Wang J, Wang H, Xu Y, Jiang K, Xu J, Ma X, Jing J, Shi H. Oncogene 41 191-203 (2022)
  49. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform. Salmón M, Paniagua G, Lechuga CG, Fernández-García F, Zarzuela E, Álvarez-Díaz R, Musteanu M, Guerra C, Caleiras E, Muñoz J, Ortega S, Drosten M, Barbacid M. Proc Natl Acad Sci U S A 118 e2023112118 (2021)
  50. Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. Selenica P, Alemar B, Matrai C, Talia KL, Veras E, Hussein Y, Oliva E, Beets-Tan RGH, Mikami Y, McCluggage WG, Kiyokawa T, Weigelt B, Park KJ, Murali R. Mod Pathol 34 1213-1225 (2021)
  51. Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. Sacco A, Federico C, Todoerti K, Ziccheddu B, Palermo V, Giacomini A, Ravelli C, Maccarinelli F, Bianchi G, Belotti A, Ribolla R, Favasuli V, Revenko AS, Macleod AR, Willis B, Cai H, Hauser J, Rooney C, Willis SE, Martin PL, Staniszewska A, Ambrose H, Hanson L, Cattaneo C, Tucci A, Rossi G, Ronca R, Neri A, Mitola S, Bolli N, Presta M, Moschetta M, Ross S, Roccaro AM. Blood 138 1705-1720 (2021)
  52. Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. Burns TF, Borghaei H, Ramalingam SS, Mok TS, Peters S. J Clin Oncol 38 4208-4218 (2020)
  53. Arginase 1 is a key driver of immune suppression in pancreatic cancer. Menjivar RE, Nwosu ZC, Du W, Donahue KL, Hong HS, Espinoza C, Brown K, Velez-Delgado A, Yan W, Lima F, Bischoff A, Kadiyala P, Salas-Escabillas D, Crawford HC, Bednar F, Carpenter E, Zhang Y, Halbrook CJ, Lyssiotis CA, Pasca di Magliano M. Elife 12 e80721 (2023)
  54. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, NCI PDXNet Consortium, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Nat Commun 12 5086 (2021)
  55. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S. Cancer Discov 10 1129-1139 (2020)
  56. ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer. Köhler J, Zhao Y, Li J, Gokhale PC, Tiv HL, Knott AR, Wilkens MK, Soroko KM, Lin M, Ambrogio C, Musteanu M, Ogino A, Choi J, Bahcall M, Bertram AA, Chambers ES, Paweletz CP, Bhagwat SV, Manro JR, Tiu RV, Jänne PA. Mol Cancer Ther 20 641-654 (2021)
  57. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Matsuo H, Yoshida K, Nakatani K, Harata Y, Higashitani M, Ito Y, Kamikubo Y, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Miyano S, Meggendorfer M, Haferlach C, Ogawa S, Adachi S. Blood Adv 4 4623-4631 (2020)
  58. Genomic and evolutionary classification of lung cancer in never smokers. Zhang T, Joubert P, Ansari-Pour N, Zhao W, Hoang PH, Lokanga R, Moye AL, Rosenbaum J, Gonzalez-Perez A, Martínez-Jiménez F, Castro A, Muscarella LA, Hofman P, Consonni D, Pesatori AC, Kebede M, Li M, Gould Rothberg BE, Peneva I, Schabath MB, Poeta ML, Costantini M, Hirsch D, Heselmeyer-Haddad K, Hutchinson A, Olanich M, Lawrence SM, Lenz P, Duggan M, Bhawsar PMS, Sang J, Kim J, Mendoza L, Saini N, Klimczak LJ, Islam SMA, Otlu B, Khandekar A, Cole N, Stewart DR, Choi J, Brown KM, Caporaso NE, Wilson SH, Pommier Y, Lan Q, Rothman N, Almeida JS, Carter H, Ried T, Kim CF, Lopez-Bigas N, Garcia-Closas M, Shi J, Bossé Y, Zhu B, Gordenin DA, Alexandrov LB, Chanock SJ, Wedge DC, Landi MT. Nat Genet 53 1348-1359 (2021)
  59. Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Kazi A, Chen L, Xiang S, Vangipurapu R, Yang H, Beato F, Fang B, Williams TM, Husain K, Underwood P, Fleming JB, Malafa M, Welsh EA, Koomen J, Trevino J, Sebti SM. Clin Cancer Res 27 4012-4024 (2021)
  60. Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. Kleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE. Cancer Lett 556 216062 (2023)
  61. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism. Sun P, Zhang X, Wang RJ, Ma QY, Xu L, Wang Y, Liao HP, Wang HL, Hu LD, Kong X, Ding J, Meng LH. J Immunother Cancer 9 e003093 (2021)
  62. Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. Nam GH, Kwon M, Jung H, Ko E, Kim SA, Choi Y, Song SJ, Kim S, Lee Y, Kim GB, Han J, Woo J, Cho Y, Jeong C, Park SY, Roberts TM, Cho YB, Kim IS. J Immunother Cancer 9 e002474 (2021)
  63. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations. Dodhiawala PB, Khurana N, Zhang D, Cheng Y, Li L, Wei Q, Seehra K, Jiang H, Grierson PM, Wang-Gillam A, Lim KH. J Clin Invest 130 4771-4790 (2020)
  64. The Ras dimer structure. Rudack T, Teuber C, Scherlo M, Güldenhaupt J, Schartner J, Lübben M, Klare J, Gerwert K, Kötting C. Chem Sci 12 8178-8189 (2021)
  65. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. Esteban-Burgos L, Wang H, Nieto P, Zheng J, Blanco-Aparicio C, Varela C, Gómez-López G, Fernández-García F, Sanclemente M, Guerra C, Drosten M, Galán J, Caleiras E, Martínez-Torrecuadrada J, Fajas L, Peng SB, Santamaría D, Musteanu M, Barbacid M. Proc Natl Acad Sci U S A 117 24415-24426 (2020)
  66. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Thyroid 30 1288-1296 (2020)
  67. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy. Zhao Y, Cao Y, Chen Y, Wu L, Hang H, Jiang C, Zhou X. Immunology 164 507-523 (2021)
  68. BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition. Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR, Sanderson MP, Kessler D, Trapani F, Arnhof H, Rumpel K, Botesteanu DA, Ettmayer P, Gerstberger T, Kofink C, Wunberg T, Zoephel A, Fu SC, Teh JL, Böttcher J, Pototschnig N, Schachinger F, Schipany K, Lieb S, Vellano CP, O'Connell JC, Mendes RL, Moll J, Petronczki M, Heffernan TP, Pearson M, McConnell DB, Kraut N. Cancer Discov (2020)
  69. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, Baroja ML, McCuaig S, Costeas C, Gabunia K, Scholler J, Posey AD, O'Hara MH, Smole A, Powell DJ, Garcia BA, Vonderheide RH, Linette GP, Carreno BM. Nat Commun 12 4365 (2021)
  70. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, Chmura SJ, Juloori A, Hoffman PC, Ferguson MK, Donington JS, Patel JD, Vokes EE, Weichselbaum RR, Bestvina CM, Segal JP, Pitroda SP. Sci Rep 11 20059 (2021)
  71. Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. JCO Precis Oncol 5 PO.20.00256 (2021)
  72. Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC. English IA, Sears RC. Cancer Discov 10 495-497 (2020)
  73. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C. Weiss A, Lorthiois E, Barys L, Beyer KS, Bomio-Confaglia C, Burks H, Chen X, Cui X, de Kanter R, Dharmarajan L, Fedele C, Gerspacher M, Guthy DA, Head V, Jaeger A, Núñez EJ, Kearns JD, Leblanc C, Maira SM, Murphy J, Oakman H, Ostermann N, Ottl J, Rigollier P, Roman D, Schnell C, Sedrani R, Shimizu T, Stringer R, Vaupel A, Voshol H, Wessels P, Widmer T, Wilcken R, Xu K, Zecri F, Farago AF, Cotesta S, Brachmann SM. Cancer Discov 12 1500-1517 (2022)
  74. Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. Kleczko EK, Hinz TK, Nguyen TT, Gurule NJ, Navarro A, Le AT, Johnson AM, Kwak J, Polhac DI, Clambey ET, Weiser-Evans M, Merrick DT, Yang MC, Patil T, Schenk EL, Heasley LE, Nemenoff RA. NPJ Precis Oncol 7 15 (2023)
  75. Enhanced SNP-sensing using DNA-templated reactions through confined hybridization of minimal substrates (CHOMS). Kim KT, Winssinger N. Chem Sci 11 4150-4157 (2020)
  76. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, Bi Y, Liu J, Rahman A, Wearne E, Ojofeitimi I, Hotaki LT, Spillman D, Pazdur R, Beaver JA, Singh H. Clin Cancer Res 28 1482-1486 (2022)
  77. Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer. Cavagna R, Escremim de Paula F, Sant'Anna D, Santana I, da Silva VD, da Silva ECA, Bacchi CE, Miziara JE, Dias JM, De Marchi P, Leal LF, Reis RM. JCO Glob Oncol 7 639-645 (2021)
  78. Identification of LncRNA Prognostic Signature Associated With Genomic Instability in Pancreatic Adenocarcinoma. Zhu J, Huang Q, Peng X, Luo C, Liu S, Liu Z, Wu X, Luo H. Front Oncol 12 799475 (2022)
  79. Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes. Coker EA, Stewart A, Ozer B, Minchom A, Pickard L, Ruddle R, Carreira S, Popat S, O'Brien M, Raynaud F, de Bono J, Al-Lazikani B, Banerji U. Mol Cancer Ther 21 1020-1029 (2022)
  80. Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells. Du R, Sullivan DK, Azizian NG, Liu Y, Li Y. BMC Cancer 21 237 (2021)
  81. Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors. Fink EA, Bardine C, Gahbauer S, Singh I, Detomasi TC, White K, Gu S, Wan X, Chen J, Ary B, Glenn I, O'Connell J, O'Donnell H, Fajtová P, Lyu J, Vigneron S, Young NJ, Kondratov IS, Alisoltani A, Simons LM, Lorenzo-Redondo R, Ozer EA, Hultquist JF, O'Donoghue AJ, Moroz YS, Taunton J, Renslo AR, Irwin JJ, García-Sastre A, Shoichet BK, Craik CS. Protein Sci 32 e4712 (2023)
  82. Loss of wild type KRAS in KRASMUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors. Liu Y, Gao GF, Minna JD, Williams NS, Westover KD. Lung Cancer 153 73-80 (2021)
  83. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer. Araujo LH, Souza BM, Leite LR, Parma SAF, Lopes NP, Malta FSV, Freire MCM. BMC Cancer 21 193 (2021)
  84. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B. J Clin Oncol 38 2140-2150 (2020)
  85. Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs. Bond MJ, Chu L, Nalawansha DA, Li K, Crews CM. ACS Cent Sci 6 1367-1375 (2020)
  86. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Nat Commun 13 4327 (2022)
  87. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, Yang R, Edwards AC, Walsh KH, Sulahian R, McFarland JM, Kapner KS, Gilbert TSK, Stalnecker CA, Javaid S, Barkovskaya A, Grover KR, Hibshman PS, Blake DR, Schaefer A, Nowak KM, Klomp JE, Hayes TK, Kassner M, Tang N, Tanaseichuk O, Chen K, Zhou Y, Kalkat M, Herring LE, Graves LM, Penn LZ, Yin HH, Aguirre AJ, Hahn WC, Cox AD, Der CJ. Cell Rep 35 109291 (2021)
  88. The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer. Lee SH, Jeon Y, Kang JH, Jang H, Lee H, Kim SY. Cancers (Basel) 12 (2020)
  89. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer. Moerland JA, Zhang D, Reich LA, Carapellucci S, Lockwood B, Leal AS, Krieger-Burke T, Aleiwi B, Ellsworth E, Liby KT. Sci Rep 10 22244 (2020)
  90. Transient Systemic Autophagy Inhibition Is Selectively and Irreversibly Deleterious to Lung Cancer. Khayati K, Bhatt V, Lan T, Alogaili F, Wang W, Lopez E, Hu ZS, Gokhale S, Cassidy L, Narita M, Xie P, White E, Guo JY. Cancer Res 82 4429-4443 (2022)
  91. Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TC, Wong CK, Choi HY, Felau I, Robertson AG, Castro MAA, Bao L, Rheinbay E, Liu EM, Trieu T, Haan D, Yau C, Hinoue T, Liu Y, Shapira O, Kumar K, Mungall KL, Zhang H, Lee JJ, Berger A, Gao GF, Zhitomirsky B, Liang WW, Zhou M, Moorthi S, Berger AH, Collisson EA, Zody MC, Ding L, Cherniack AD, Getz G, Elemento O, Benz CC, Stuart J, Zenklusen JC, Beroukhim R, Chang JC, Campbell JD, Hayes DN, Yang L, Laird PW, Weinstein JN, Kwiatkowski DJ, Tsao MS, Travis WD, Khurana E, Berman BP, Hoadley KA, Robine N, TCGA Research Network, Meyerson M, Govindan R, Imielinski M. Cell Rep 34 108707 (2021)
  92. YAP/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer. Yamazaki M, Hino S, Usuki S, Miyazaki Y, Oda T, Nakao M, Ito T, Yamagata K. EMBO J 42 e112614 (2023)
  93. A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS. Bery N, Miller A, Rabbitts T. Nat Commun 11 3233 (2020)
  94. AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis. Kim DG, Choi Y, Lee Y, Lim S, Kong J, Song J, Roh Y, Harmalkar DS, Lee K, Goo JI, Cho HY, Mushtaq AU, Lee J, Park SH, Kim D, Min BS, Lee KY, Jeon YH, Lee S, Lee K, Kim S. Nat Commun 13 2572 (2022)
  95. Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation. Gonzalez-Del Pino GL, Li K, Park E, Schmoker AM, Ha BH, Eck MJ. Proc Natl Acad Sci U S A 118 e2107207118 (2021)
  96. Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, Colliver E, Enfield K, Bah N, Kelly G, Tsang VSK, Mugarza E, Moore C, Hobson P, Levi D, Molina-Arcas M, Swanton C, Downward J. Nat Commun 12 5906 (2021)
  97. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Tian J, Chen JH, Chao SX, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, Allen JN, Abrams TA, Clark JW, Enzinger AC, Enzinger PC, Klempner SJ, McCleary NJ, Meyerhardt JA, Ryan DP, Yurgelun MB, Kanter K, Van Seventer EE, Baiev I, Chi G, Jarnagin J, Bradford WB, Wong E, Michel AG, Fetter IJ, Siravegna G, Gemma AJ, Sharpe A, Demehri S, Leary R, Campbell CD, Yilmaz O, Getz GA, Parikh AR, Hacohen N, Corcoran RB. Nat Med 29 458-466 (2023)
  98. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C. Mortier J, Friberg A, Badock V, Moosmayer D, Schroeder J, Steigemann P, Siegel F, Gradl S, Bauser M, Hillig RC, Briem H, Eis K, Bader B, Nguyen D, Christ CD. ChemMedChem 15 827-832 (2020)
  99. Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy. Hattori T, Maso L, Araki KY, Koide A, Hayman J, Akkapeddi P, Bang I, Neel BG, Koide S. Cancer Discov 13 132-145 (2023)
  100. Generation of Non-Small Cell Lung Cancer Patient-Derived Xenografts to Study Intratumor Heterogeneity. Kanaki Z, Voutsina A, Markou A, Pateras IS, Potaris K, Avgeris M, Makrythanasis P, Athanasiadis EI, Vamvakaris I, Patsea E, Vachlas K, Lianidou E, Georgoulias V, Kotsakis A, Klinakis A. Cancers (Basel) 13 2446 (2021)
  101. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. Zhang S, Iyer S, Ran H, Dolgalev I, Gu S, Wei W, Foster CJR, Loomis CA, Olvera N, Dao F, Levine DA, Weinberg RA, Neel BG. Cancer Discov 11 362-383 (2021)
  102. Genomic characteristics of invasive mucinous adenocarcinoma of the lung with multiple pulmonary sites of involvement. Kim M, Hwang J, Kim KA, Hwang S, Lee HJ, Jung JY, Lee JG, Cha YJ, Shim HS. Mod Pathol 35 202-209 (2022)
  103. Growth-rate model predicts in vivo tumor response from in vitro data. Diegmiller R, Salphati L, Alicke B, Wilson TR, Stout TJ, Hafner M. CPT Pharmacometrics Syst Pharmacol 11 1183-1193 (2022)
  104. High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer. Feng HB, Chen Y, Xie Z, Jiang J, Zhong YM, Guo WB, Yan WQ, Lv ZY, Lu DX, Liang HL, Xu FP, Yang JJ, Yang XN, Zhou Q, Zhang DK, Zhang Z, Chuai SK, Zhang HH, Wu YL, Zhang XC. Thorac Cancer 12 2564-2573 (2021)
  105. Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. Levin N, Paria BC, Vale NR, Yossef R, Lowery FJ, Parkhurst MR, Yu Z, Florentin M, Cafri G, Gartner JJ, Shindorf ML, Ngo LT, Ray S, Kim SP, Copeland AR, Robbins PF, Rosenberg SA. Clin Cancer Res 27 5084-5095 (2021)
  106. Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. Maroni G, Bassal MA, Krishnan I, Fhu CW, Savova V, Zilionis R, Maymi VA, Pandell N, Csizmadia E, Zhang J, Storti B, Castaño J, Panella R, Li J, Gustafson CE, Fox S, Levy RD, Meyerovitz CV, Tramontozzi PJ, Vermilya K, De Rienzo A, Crucitta S, Bassères DS, Weetall M, Branstrom A, Giorgetti A, Ciampi R, Del Re M, Danesi R, Bizzarri R, Yang H, Kocher O, Klein AM, Welner RS, Bueno R, Magli MC, Clohessy JG, Ali A, Tenen DG, Levantini E. Commun Biol 4 370 (2021)
  107. KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. Paniagua G, Jacob HKC, Brehey O, García-Alonso S, Lechuga CG, Pons T, Musteanu M, Guerra C, Drosten M, Barbacid M. Mol Oncol 16 3066-3081 (2022)
  108. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P, Hong DS, Lito P, Tran Q, Jones S, Anderson A, Hindoyan A, Snyder W, Skoulidis F, Li BT. J Clin Oncol 41 3311-3317 (2023)
  109. MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. Yang B, Li X, Fu Y, Guo E, Ye Y, Li F, Liu S, Xiao R, Liu C, Lu F, Huang J, Qin T, Han L, Peng G, Mills GB, Sun C, Chen G. Cancer Res 81 2714-2729 (2021)
  110. NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. Jain P, Dvorkin-Gheva A, Mollen E, Malbeteau L, Xie M, Jessa F, Dhavarasa P, Chung S, Brown KR, Jang GH, Vora P, Notta F, Moffat J, Hedley D, Boutros PC, Wouters BG, Koritzinsky M. Sci Adv 7 eabf7114 (2021)
  111. Overcoming Resistance to Drugs Targeting KRASG12C Mutation. Jiao D, Yang S. Innovation (N Y) 1 (2020)
  112. Potential of phenothiazines to synergistically block calmodulin and reactivate PP2A in cancer cells. Manoharan GB, Okutachi S, Abankwa D. PLoS One 17 e0268635 (2022)
  113. Predictive molecular pathology in the time of COVID-19. Malapelle U, De Luca C, Iaccarino A, Pepe F, Pisapia P, Russo M, Sgariglia R, Nacchio M, Vigliar E, Bellevicine C, Schmitt FC, Troncone G. J Clin Pathol (2020)
  114. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. Wu SG, Liao WY, Su KY, Yu SL, Huang YL, Yu CJ, Chih-Hsin Yang J, Shih JY. JTO Clin Res Rep 2 100140 (2021)
  115. RAS-mediated tumor stress adaptation and the targeting opportunities it presents. Redding A, Aplin AE, Grabocka E. Dis Model Mech 15 dmm049280 (2022)
  116. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. Tsai YS, Woodcock MG, Azam SH, Thorne LB, Kanchi KL, Parker JS, Vincent BG, Pecot CV. J Clin Invest 132 e155523 (2022)
  117. Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Chang L, Jung NY, Atari A, Rodriguez DJ, Kesar D, Song TY, Rees MG, Ronan M, Li R, Ruiz P, Chaturantabut S, Ito T, van Tienen LM, Tseng YY, Roth JA, Sellers WR. Nat Genet 55 1709-1720 (2023)
  118. The Achilles' Heel of Pancreatic Cancer: Targeting pancreatic cancer's unique immunologic characteristics and metabolic dependencies in clinical trials. Siolas D, Morrissey C, Oberstein PE. J Pancreatol 3 121-131 (2020)
  119. The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors. Sakamoto K, Lin B, Nunomura K, Izawa T, Nakagawa S. Sci Rep 12 8121 (2022)
  120. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. Diehl JN, Klomp JE, Snare KR, Hibshman PS, Blake DR, Kaiser ZD, Gilbert TSK, Baldelli E, Pierobon M, Papke B, Yang R, Hodge RG, Rashid NU, Petricoin EF, Herring LE, Graves LM, Cox AD, Der CJ. J Biol Chem 297 101335 (2021)
  121. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY. Int J Mol Sci 22 7508 (2021)
  122. A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133. Keats MA, Han JJW, Lee YH, Lee CS, Luo J. Cancer Res 83 2816-2823 (2023)
  123. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Aung KL, McWhirter E, Welch S, Wang L, Lovell S, Stayner LA, Ali S, Malpage A, Makepeace B, Ramachandran M, Jang GH, Gallinger S, Zhang T, Stockley TL, Fischer SE, Dhani N, Hedley D, Knox JJ, Siu LL, Goodwin R, Bedard PL. J Gastrointest Oncol 13 3216-3226 (2022)
  124. A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. Gurule NJ, McCoach CE, Hinz TK, Merrick DT, Van Bokhoven A, Kim J, Patil T, Calhoun J, Nemenoff RA, Tan AC, Doebele RC, Heasley LE. NPJ Precis Oncol 5 41 (2021)
  125. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Hagenbeek TJ, Zbieg JR, Hafner M, Mroue R, Lacap JA, Sodir NM, Noland CL, Afghani S, Kishore A, Bhat KP, Yao X, Schmidt S, Clausen S, Steffek M, Lee W, Beroza P, Martin S, Lin E, Fong R, Di Lello P, Kubala MH, Yang MN, Lau JT, Chan E, Arrazate A, An L, Levy E, Lorenzo MN, Lee HJ, Pham TH, Modrusan Z, Zang R, Chen YC, Kabza M, Ahmed M, Li J, Chang MT, Maddalo D, Evangelista M, Ye X, Crawford JJ, Dey A. Nat Cancer 4 812-828 (2023)
  126. Arene Ru(II) Complexes Acted as Potential KRAS G-Quadruplex DNA Stabilizer Induced DNA Damage Mediated Apoptosis to Inhibit Breast Cancer Progress. Qian J, Liu R, Liu N, Yuan C, Wu Q, Chen Y, Tan W, Mei W. Molecules 27 3046 (2022)
  127. Atropisomerism in the Pharmaceutically Relevant Realm. Basilaia M, Chen MH, Secka J, Gustafson JL. Acc Chem Res 55 2904-2919 (2022)
  128. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer. Li K, Liu Y, Ding Y, Zhang Z, Feng J, Hu J, Chen J, Lian Z, Chen Y, Hu K, Chen Z, Cai Z, Liu M, Pang X. J Clin Invest 132 e161308 (2022)
  129. Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ. Martinez NG, Thieker DF, Carey LM, Rasquinha JA, Kistler SK, Kuhlman BA, Campbell SL. J Mol Biol 433 166838 (2021)
  130. Broad-spectrum rescue compounds for structural p53 mutations: perspective on 'Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site'. Wu JL, Chen S, Lu M. J Mol Cell Biol 13 155-157 (2021)
  131. Cancer drugs are closing in on some of the deadliest mutations. Ledford H. Nature 610 620-622 (2022)
  132. Characterizing the KRAS G12C mutation in metastatic colorectal cancer: a population-based cohort and assessment of expression differences in The Cancer Genome Atlas. Li M, Keshavarz-Rahaghi F, Ladua G, Swanson L, Speers C, Renouf DJ, Lim HJ, Davies JM, Gill S, Stuart HC, Yip S, Loree JM. Ther Adv Med Oncol 14 17588359221097940 (2022)
  133. Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies. Ardalan B, Azqueta J, Sleeman D. J Pancreat Cancer 7 65-70 (2021)
  134. Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. Fan F, Ghosh S, Powell R, Roszik J, Park Y, Sobieski M, Sorokin A, Stephan C, Kopetz S, Ellis LM, Bhattacharya R. PLoS One 18 e0281063 (2023)
  135. Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting-Role of Academic and Hybrid Modeling. Salgia R, Mambetsariev I, Tan T, Schwer A, Pearlstein DP, Chehabi H, Baroz A, Fricke J, Pharaon R, Romo H, Waddington T, Babikian R, Buck L, Kulkarni P, Cianfrocca M, Djulbegovic B, Pal SK. J Clin Med 9 (2020)
  136. Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component. Suzuki M, Kasajima R, Yokose T, Ito H, Shimizu E, Hatakeyama S, Yokoyama K, Yamaguchi R, Furukawa Y, Miyano S, Imoto S, Yoshioka E, Washimi K, Okubo Y, Kawachi K, Sato S, Miyagi Y. Transl Lung Cancer Res 10 1292-1304 (2021)
  137. D-1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity. Shi Z, Weng J, Niu H, Yang H, Liu R, Weng Y, Zhu Q, Zhang Y, Tao L, Wang Z, Huh SJ, Jiang Y, Mei H, Dai X, Zhang L, Wang Y. Cancer Sci 114 2951-2960 (2023)
  138. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity. Valencia K, Echepare M, Teijeira Á, Teijeira Á, Pasquier A, Bértolo C, Sainz C, Tamayo I, Picabea B, Bosco G, Thomas R, Agorreta J, López-Picazo JM, Frigola J, Amat R, Calvo A, Felip E, Melero I, Montuenga LM. J Exp Med 219 e20220726 (2022)
  139. Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening. Du Y, Li X, Niu Q, Mo X, Qui M, Ma T, Kuo CJ, Fu H. J Mol Cell Biol 12 630-643 (2020)
  140. Editorial Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Parums DV. Med Sci Monit 28 e938746 (2022)
  141. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study. Wang W, Shao L, Xu Y, Song Z, Lou G, Zhang Y, Chen M. BMC Pulm Med 22 179 (2022)
  142. Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling. Zhang B, Zhang Y, Zhang J, Liu P, Jiao B, Wang Z, Ren R. Adv Sci (Weinh) 8 e2100250 (2021)
  143. Frizzled-7-targeting antibody (SHH002-hu1) potently suppresses non-small-cell lung cancer via Wnt/β-catenin signaling. Li K, Mao S, Li X, Zhao H, Wang J, Wang C, Wu L, Zhang K, Yang H, Jin M, Zhou Z, Wang J, Huang G, Xie W. Cancer Sci 114 2109-2122 (2023)
  144. GTP hydrolysis is modulated by Arg34 in the RASopathy-associated KRASP34R. Bera AK, Lu J, Lu C, Li L, Gondi S, Yan W, Nelson A, Zhang G, Westover KD. Birth Defects Res 112 708-717 (2020)
  145. Genetic and pharmacological interrogation of cancer vulnerability using a multiplexed cell line screening platform. Xia Y, Ji X, Jang IS, Surka C, Hsu C, Wang K, Rolfe M, Bence N, Lu G. Commun Biol 4 834 (2021)
  146. Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. Zambetti NA, Firestone AJ, Remsberg JR, Huang BJ, Wong JC, Long AM, Predovic M, Suciu RM, Inguva A, Kogan SC, Haigis KM, Cravatt BF, Shannon K. Blood 135 1772-1782 (2020)
  147. Genomic Landscape of RTK/RAS Pathway and Tumor Immune Infiltration as Prognostic Indicator of Lung Adenocarcinoma. Yin XQ, Yin XH, Yu YQ, Xu L, Zhang M. Front Oncol 12 924239 (2022)
  148. Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer. Fujita K, Nakayama M, Sata M, Nagai Y, Hisata S, Mato N, Suzuki T, Bando M, Hizawa N, Hagiwara K. Cancer Med 10 8595-8603 (2021)
  149. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, Janku F, Skoulidis F, Heymach JV, Kopetz S, Meric-Bernstam F, Hong DS. JCO Precis Oncol 6 e2100547 (2022)
  150. Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS. Pinheiro G, Pereira T, Dias C, Freitas C, Hespanhol V, Costa JL, Cunha A, Oliveira HP. Sci Rep 10 3625 (2020)
  151. Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy. Wang E, Cesano A, Butterfield LH, Marincola F. J Immunother Cancer 8 (2020)
  152. In situ identification of cellular drug targets in mammalian tissue. Pang Z, Schafroth MA, Ogasawara D, Wang Y, Nudell V, Lal NK, Yang D, Wang K, Herbst DM, Ha J, Guijas C, Blankman JL, Cravatt BF, Ye L. Cell 185 1793-1805.e17 (2022)
  153. Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Ma Y, Schulz B, Trakooljul N, Al Ammar M, Sekora A, Sender S, Hadlich F, Zechner D, Weiss FU, Lerch MM, Jaster R, Junghanss C, Murua Escobar H. Cancers (Basel) 14 4467 (2022)
  154. Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS. Ilter M, Kasmer R, Jalalypour F, Atilgan C, Topcu O, Karakas N, Sensoy O. Elife 11 e79747 (2022)
  155. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers. Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, Mohammad RM, Shields AF, Azmi AS. Cancer Res Commun 2 342-352 (2022)
  156. Integrated Molecular Analysis Reveals 2 Distinct Subtypes of Pure Seminoma of the Testis. Medvedev KE, Savelyeva AV, Chen KS, Bagrodia A, Jia L, Grishin NV. Cancer Inform 21 11769351221132634 (2022)
  157. KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Mao Z, Xiao H, Shen P, Yang Y, Xue J, Yang Y, Shang Y, Zhang L, Li X, Zhang Y, Du Y, Chen CC, Guo RT, Zhang Y. Cell Discov 8 5 (2022)
  158. KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. Chang WH, Nguyen TT, Hsu CH, Bryant KL, Kim HJ, Ying H, Erickson JW, Der CJ, Cerione RA, Antonyak MA. Cancer Lett 517 66-77 (2021)
  159. KRASG12C mutation-induced TOPK overexpression contributes to tumour progression in non-small cell lung cancer. Cai C, Yao S, Zou Y, Lu H, Chen X, Wang Y, Zheng K, Zhu F, Wang Y, Xiong H, Zhu J. J Cell Mol Med 27 1637-1652 (2023)
  160. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, Sockwell AM, Kirtley ML, Morse SJ, Moreno Diaz BA, Kim MP, Feng N, Lopez AM, Guerrero PA, Paradiso F, Sugimoto H, Arian KA, Ying H, Barekatain Y, Sthanam LK, Kelly PJ, Maitra A, Heffernan TP, Kalluri R. Cancer Cell 41 1606-1620.e8 (2023)
  161. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. Huang RSP, Severson E, Haberberger J, Duncan DL, Hemmerich A, Edgerly C, Ferguson NL, Frampton G, Owens C, Williams E, Elvin J, Vergilio JA, Killian JK, Lin D, Morley S, McEwan D, Holmes O, Danziger N, Cohen MB, Sathyan P, McGregor K, Reddy P, Venstrom J, Anhorn R, Alexander B, Brown C, Ross JS, Ramkissoon SH. Pathol Oncol Res 27 592997 (2021)
  162. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, Pataer A, Lu D, Han D, Malmberg E, Chan DW, Wang X, Savage SR, Mao S, Yu J, Peng F, Yan L, Meng H, Maneix L, Han Y, Chen Y, Yao W, Chang EC, Catic A, Lin X, Miles G, Huang P, Sun Z, Burt B, Wang H, Wang J, Yao QC, Zhang B, Roth JA, O'Malley BW, Ellis MJ, Rimawi MF, Ying H, Chen X. Science 381 eabn4180 (2023)
  163. Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. Wu PK, Hong SK, Starenki D, Oshima K, Shao H, Gestwicki JE, Tsai S, Park JI. Oncogene 39 4257-4270 (2020)
  164. Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities. Esposito R, Polidori T, Meise DF, Pulido-Quetglas C, Chouvardas P, Forster S, Schaerer P, Kobel A, Schlatter J, Kerkhof E, Roemmele M, Rice ES, Zhu L, Lanzós A, Guillen-Ramirez HA, Basile G, Carrozzo I, Vancura A, Ullrich S, Andrades A, Harvey D, Medina PP, Ma PC, Haefliger S, Wang X, Martinez I, Ochsenbein AF, Riether C, Johnson R. Cell Genom 2 100171 (2022)
  165. Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles. Hoffman TE, Nangia V, Ill CR, Passanisi VJ, Armstrong C, Yang C, Spencer SL. Sci Signal 16 eade8744 (2023)
  166. Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T-Cells to Activation-Induced Cell Death in Colorectal Cancer. Liu H, Liang Z, Cheng S, Huang L, Li W, Zhou C, Zheng X, Li S, Zeng Z, Kang L. Adv Sci (Weinh) 10 e2203757 (2023)
  167. Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients. Guo G, Li G, Liu Y, Li H, Guo Q, Liu J, Yang X, Shou T, Shi Y. Front Oncol 11 621422 (2021)
  168. Novel potent azetidine-based compounds irreversibly inhibit Stat3 activation and induce antitumor response against human breast tumor growth in vivo. Yue P, Zhu Y, Brotherton-Pleiss C, Fu W, Verma N, Chen J, Nakamura K, Chen W, Chen Y, Alonso-Valenteen F, Mikhael S, Medina-Kauwe L, Kershaw KM, Celeridad M, Pan S, Limpert AS, Sheffler DJ, Cosford NDP, Shiao SL, Tius MA, Lopez-Tapia F, Turkson J. Cancer Lett 534 215613 (2022)
  169. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer. Cheng DK, Oni TE, Thalappillil JS, Park Y, Ting HC, Alagesan B, Prasad NV, Addison K, Rivera KD, Pappin DJ, Van Aelst L, Tuveson DA. Proc Natl Acad Sci U S A 118 e2016904118 (2021)
  170. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. Adhikari H, Kattan WE, Kumar S, Zhou P, Hancock JF, Counter CM. Nat Commun 12 5248 (2021)
  171. Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47. Hu H, Cheng R, Wang Y, Wang X, Wu J, Kong Y, Zhan S, Zhou Z, Zhu H, Yu R, Liang G, Wang Q, Zhu X, Zhang CY, Yin R, Yan C, Chen X. J Clin Invest 133 e153470 (2023)
  172. Pathogenic signaling in multiple myeloma. Bolomsky A, Young RM. Semin Oncol 49 27-40 (2022)
  173. Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression. Jiang W, Li H, Liu X, Zhang J, Zhang W, Li T, Liu L, Yu X. Theranostics 10 11507-11519 (2020)
  174. Prognostic and Immunotherapeutic Roles of KRAS in Pan-Cancer. Yang K, Li C, Liu Y, Gu X, Jiang L, Shi L. Cells 11 1427 (2022)
  175. Promotion of squamous cell carcinoma tumorigenesis by oncogene-mediated THG-1/TSC22D4 phosphorylation. Goto N, Suzuki H, Zheng L, Okano Y, Okita Y, Watanabe Y, Kato Y, Kato M. Cancer Sci 114 3972-3983 (2023)
  176. Protein Electric Fields Enable Faster and Longer-Lasting Covalent Inhibition of β-Lactamases. Ji Z, Kozuch J, Mathews II, Diercks CS, Shamsudin Y, Schulz MA, Boxer SG. J Am Chem Soc 144 20947-20954 (2022)
  177. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells. Wang Z, Kang B, Gao Q, Huang L, Di J, Fan Y, Yu J, Jiang B, Gao F, Wang D, Sun H, Gu Y, Li J, Su X. Cancer Sci 112 3895-3910 (2021)
  178. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging. Sutton MN, Gammon ST, Muzzioli R, Pisaneschi F, Radaram B, Yang P, Piwnica-Worms D. Mol Imaging Biol 24 498-509 (2022)
  179. RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Coltro G, Rotunno G, Mannelli L, Mannarelli C, Fiaccabrino S, Romagnoli S, Bartalucci N, Ravenda E, Gelli E, Sant'Antonio E, Patnaik MM, Tefferi A, Vannucchi AM, Guglielmelli P. Blood Adv 4 3677-3687 (2020)
  180. Rational antibody design for undruggable targets using kinetically controlled biomolecular probes. Trkulja CL, Jungholm O, Davidson M, Jardemark K, Marcus MM, Hägglund J, Karlsson A, Karlsson R, Bruton J, Ivarsson N, Srinivasa SP, Cavallin A, Svensson P, Jeffries GDM, Christakopoulou MN, Reymer A, Ashok A, Willman G, Papadia D, Johnsson E, Orwar O. Sci Adv 7 eabe6397 (2021)
  181. Ryanodine receptor 2 promotes colorectal cancer metastasis by the ROS/BACH1 axis. Chen T, Zhang X, Ding X, Feng J, Zhang X, Xie D, Wang X. Mol Oncol 17 695-709 (2023)
  182. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling. Fedele C, Li S, Teng KW, Foster CJR, Peng D, Ran H, Mita P, Geer MJ, Hattori T, Koide A, Wang Y, Tang KH, Leinwand J, Wang W, Diskin B, Deng J, Chen T, Dolgalev I, Ozerdem U, Miller G, Koide S, Wong KK, Neel BG. J Exp Med 218 (2021)
  183. SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC. Ruiz CF, Montal ED, Haley JA, Bott AJ, Haley JD. FASEB J 34 10574-10589 (2020)
  184. Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Adachi Y, Kimura R, Hirade K, Yanase S, Nishioka Y, Kasuga N, Yamaguchi R, Ebi H. Nat Cancer 4 829-843 (2023)
  185. Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression. Gao Q, Ouyang W, Kang B, Han X, Xiong Y, Ding R, Li Y, Wang F, Huang L, Chen L, Wang D, Dong X, Zhang Z, Li Y, Ze B, Hou Y, Yang H, Ma Y, Gu Y, Chao CC. Theranostics 10 5137-5153 (2020)
  186. Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition. Catalano A, Adlesic M, Kaltenbacher T, Klar RFU, Albers J, Seidel P, Brandt LP, Hejhal T, Busenhart P, Röhner N, Zodel K, Fritsch K, Wild PJ, Duyster J, Fritsch R, Brummer T, Frew IJ. Cancers (Basel) 13 1852 (2021)
  187. Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. Papke B, Azam SH, Feng AY, Gutierrez-Ford C, Huggins H, Pallan PS, Van Swearingen AED, Egli M, Cox AD, Der CJ, Pecot CV. ACS Pharmacol Transl Sci 4 703-712 (2021)
  188. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Kobayashi Y, Chhoeu C, Li J, Price KS, Kiedrowski LA, Hutchins JL, Hardin AI, Wei Z, Hong F, Bahcall M, Gokhale PC, Jänne PA. Nature 603 335-342 (2022)
  189. Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells. Han JH, Kim YK, Kim H, Lee J, Oh MJ, Kim SB, Kim M, Kim KH, Yoon HJ, Lee MS, Minna JD, White MA, Kim HS. Cancer Commun (Lond) 42 716-749 (2022)
  190. Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer. Ganguly A, Yoo E. Trends Pharmacol Sci 43 536-537 (2022)
  191. Stability and Cell Permeability of Sulfonyl Fluorides in the Design of Lys-Covalent Antagonists of Protein-Protein Interactions. Gambini L, Udompholkul P, Salem AF, Baggio C, Pellecchia M. ChemMedChem 15 2176-2184 (2020)
  192. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Yan L, Tu B, Yao J, Gong J, Carugo A, Bristow CA, Wang Q, Zhu C, Dai B, Kang Y, Han L, Feng N, Jin Y, Fleming J, Heffernan TP, Yao W, Ying H. Cancer Res 81 4054-4065 (2021)
  193. Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer. Lee H, Cai F, Kelekar N, Velupally NK, Kim J. Cells 11 176 (2022)
  194. Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R. Qi WL, Li HY, Wang Y, Xu L, Deng JT, Zhang X, Wang YX, Meng LH. Acta Pharmacol Sin 44 1083-1094 (2023)
  195. The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells. Tisi R, Spinelli M, Palmioli A, Airoldi C, Cazzaniga P, Besozzi D, Nobile MS, Mazzoleni E, Arnhold S, De Gioia L, Grandori R, Peri F, Vanoni M, Sacco E. Front Mol Biosci 8 625979 (2021)
  196. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer. Entrialgo-Cadierno R, Cueto-Ureña C, Welch C, Feliu I, Macaya I, Vera L, Morales X, Michelina SV, Scaparone P, Lopez I, Darbo E, Erice O, Vallejo A, Moreno H, Goñi-Salaverri A, Lara-Astiaso D, Halberg N, Cortes-Dominguez I, Guruceaga E, Ambrogio C, Lecanda F, Vicent S. Mol Cancer 22 86 (2023)
  197. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Mugarza E, van Maldegem F, Boumelha J, Moore C, Rana S, Llorian Sopena M, East P, Ambler R, Anastasiou P, Romero-Clavijo P, Valand K, Cole M, Molina-Arcas M, Downward J. Sci Adv 8 eabm8780 (2022)
  198. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. Kurth I, Yamaguchi N, Andreu-Agullo C, Tian HS, Sridhar S, Takeda S, Gonsalves FC, Loo JM, Barlas A, Manova-Todorova K, Busby R, Bendell JC, Strauss J, Fakih M, McRee AJ, Hendifar AE, Rosen LS, Cercek A, Wasserman R, Szarek M, Spector SL, Raza S, Tavazoie MF, Tavazoie SF. Sci Adv 7 eabi7511 (2021)
  199. Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China. Zhou Y, Ge F, Du Y, Li Q, Cai J, Liu X, Guo Y, Shen Z, Duan L, Huang Z, Yao F, Zhu C, Shi H, Huang Y. Front Oncol 11 644895 (2021)
  200. Utilization of cytologic cell blocks for targeted sequencing of solid tumors. Vormittag-Nocito E, Kumar R, Narayan KD, Chen Z, David O, Behm F, Mohapatra G. Cancer Med 12 4042-4063 (2023)
  201. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRASG12C Inhibitors. Luo L, Zheng T, Wang Q, Liao Y, Zheng X, Zhong A, Huang Z, Luo H. Pharmaceuticals (Basel) 15 584 (2022)
  202. Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non-small cell lung cancer. Sayama H, Marcantonio D, Nagashima T, Shimazaki M, Minematsu T, Apgar JF, Burke JM, Wille L, Nagasaka Y, Kirouac DC. CPT Pharmacometrics Syst Pharmacol 10 864-877 (2021)
  203. Whole-Genome Analysis of De Novo Somatic Point Mutations Reveals Novel Mutational Biomarkers in Pancreatic Cancer. Ghareyazi A, Mohseni A, Dashti H, Beheshti A, Dehzangi A, Rabiee HR, Alinejad-Rokny H. Cancers (Basel) 13 4376 (2021)
  204. [Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy]. Jiang L, Zhang J, Hu J, Qi H, Xu H. Zhongguo Fei Ai Za Zhi 25 477-481 (2022)
  205. α4-α5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death. Abuasaker B, Garrido E, Vilaplana M, Gómez-Zepeda JD, Brun S, Garcia-Cajide M, Mauvezin C, Jaumot M, Pujol MD, Rubio-Martínez J, Agell N. Int J Mol Sci 24 748 (2023)
  206. 143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models. Xu LS, Zheng SX, Mei LH, Yang KX, Wang YF, Zhou Q, Kong XT, Zheng MY, Jiang HL, Xie CY. Acta Pharmacol Sin 44 1475-1486 (2023)
  207. A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination. Miyamoto-Sato E, Imanishi S, Huang L, Itakura S, Iwasaki Y, Ishizaka M. Molecules 28 5600 (2023)
  208. In silico epitope prediction analyses highlight the potential for distracting antigen immunodominance with allogeneic cancer vaccines. James CA, Ronning P, Cullinan D, Cotto KC, Barnell EK, Campbell KM, Skidmore ZL, Sanford DE, Goedegebuure SP, Gillanders WE, Griffith OL, Hawkins WG, Griffith M. Cancer Res Commun 1 115-126 (2021)
  209. K-Ras-Activated Cells Can Develop into Lung Tumors When Runx3-Mediated Tumor Suppressor Pathways Are Abrogated. Lee YS, Lee JY, Song SH, Kim DM, Lee JW, Chi XZ, Ito Y, Bae SC. Mol Cells 43 889-897 (2020)
  210. USH2A mutation and specific driver mutation subtypes are associated with clinical efficacy of immune checkpoint inhibitors in lung cancer. Yang D, Feng Y, Lu H, Chen K, Xu J, Li P, Wang T, Xia D, Wu Y. J Zhejiang Univ Sci B 24 143-156 (2023)
  211. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy. Lin J, Cai Y, Ma Y, Pan J, Wang Z, Zhang J, Liu Y, Zhao Z. Int J Mol Sci 24 5332 (2023)
  212. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition. Barrios-Bernal P, Lucio-Lozada J, Ramos-Ramírez M, Hernández-Pedro N, Arrieta O. Int J Mol Sci 24 4331 (2023)
  213. A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. Muscarella P, Bekaii-Saab T, McIntyre K, Rosemurgy A, Ross SB, Richards DA, Fisher WE, Flynn PJ, Mattson A, Coeshott C, Roder H, Roder J, Harrell FE, Cohn A, Rodell TC, Apelian D. J Pancreat Cancer 7 8-19 (2021)
  214. A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability. Guiley KZ, Shokat KM. Cancer Discov 13 56-69 (2023)
  215. A covalent inhibitor of the YAP-TEAD transcriptional complex identified by high-throughput screening. Nutsch K, Song L, Chen E, Hull M, Chatterjee AK, Chen JJ, Bollong MJ. RSC Chem Biol 4 894-905 (2023)
  216. A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes. Schubert L, Le AT, Hinz TK, Navarro AC, Nelson-Taylor SK, Nemenoff RA, Heasley LE, Doebele RC. Biol Open 12 bio059994 (2023)
  217. A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95. Rehl KM, Selvakumar J, Pitsch RL, Hoang D, Arumugam K, Harshman SW, Gorfe AA, Cho KJ. Life Sci Alliance 6 e202302094 (2023)
  218. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers. Cheng R, Li F, Zhang M, Xia X, Wu J, Gao X, Zhou H, Zhang Z, Huang N, Yang X, Zhang Y, Shen S, Kang T, Liu Z, Xiao F, Yao H, Xu J, Yan C, Zhang N. Cell Res 33 30-45 (2023)
  219. A prime editor mouse to model a broad spectrum of somatic mutations in vivo. Ely ZA, Mathey-Andrews N, Naranjo S, Gould SI, Mercer KL, Newby GA, Cabana CM, Rideout WM, Jaramillo GC, Khirallah JM, Holland K, Randolph PB, Freed-Pastor WA, Davis JR, Kulstad Z, Westcott PMK, Lin L, Anzalone AV, Horton BL, Pattada NB, Shanahan SL, Ye Z, Spranger S, Xu Q, Sánchez-Rivera FJ, Liu DR, Jacks T. Nat Biotechnol (2023)
  220. AZD4625 is a Potent and Selective Inhibitor of KRASG12C. Chakraborty A, Hanson L, Robinson D, Lewis H, Bickerton S, Davies M, Polanski R, Whiteley R, Koers A, Atkinson J, Baker T, Del Barco Barrantes I, Ciotta G, Kettle JG, Magiera L, Martins CP, Peter A, Wigmore E, Underwood Z, Cosulich S, Niedbala M, Ross S. Mol Cancer Ther 21 1535-1546 (2022)
  221. Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate. Vuu I, Dahal UP, Wang Z, Shen X, Rodgers J, Wahlstrom J, Houk B. Cancer Chemother Pharmacol 90 357-367 (2022)
  222. Accelerated Identification of Cell Active KRAS Inhibitory Macrocyclic Peptides using Mixture Libraries and Automated Ligand Identification System (ALIS) Technology. Garrigou M, Sauvagnat B, Duggal R, Boo N, Gopal P, Johnston JM, Partridge A, Sawyer T, Biswas K, Boyer N. J Med Chem 65 8961-8974 (2022)
  223. Activity-based protein profiling - finding general solutions to specific problems. Cravatt BF. Isr J Chem 63 e202300029 (2023)
  224. Adagrasib: A landmark in the KRASG12C-mutated NSCLC. Tian H, Yang Z, He J. MedComm (2020) 3 e190 (2022)
  225. An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations. Boumelha J, de Carné Trécesson S, Law EK, Romero-Clavijo P, Coelho MA, Ng KW, Mugarza E, Moore C, Rana S, Caswell DR, Murillo M, Hancock DC, Argyris PP, Brown WL, Durfee C, Larson LK, Vogel RI, Suárez-Bonnet A, Priestnall SL, East P, Ross SJ, Kassiotis G, Molina-Arcas M, Swanton C, Harris R, Downward J. Cancer Res 82 3435-3448 (2022)
  226. An In Vivo Inflammatory Loop Potentiates KRAS Blockade. Arendt KAM, Ntaliarda G, Armenis V, Kati D, Henning C, Giotopoulou GA, Pepe MAA, Klotz LV, Lamort AS, Hatz RA, Kobold S, Schamberger AC, Stathopoulos GT. Biomedicines 10 592 (2022)
  227. An integrated model for predicting KRAS dependency. Tsai YS, Chareddy YS, Price BA, Parker JS, Pecot CV. PLoS Comput Biol 19 e1011095 (2023)
  228. An integrated model of acinar to ductal metaplasia-related N7-methyladenosine regulators predicts prognosis and immunotherapy in pancreatic carcinoma based on digital spatial profiling. Yang H, Messina-Pacheco J, Corredor ALG, Gregorieff A, Liu JL, Nehme A, Najafabadi HS, Riazalhosseini Y, Gao B, Gao ZH. Front Immunol 13 961457 (2022)
  229. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy. Yang M, Davis TB, Pflieger L, Nebozhyn MV, Loboda A, Wang H, Schell MJ, Thota R, Pledger WJ, Yeatman TJ. BMC Cancer 22 256 (2022)
  230. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers. Khan HY, Nagasaka M, Aboukameel A, Alkhalili O, Uddin MH, Bannoura SF, Mzannar Y, Azar I, Beal EW, Tobon ME, Kim SH, Beydoun R, Baloglu E, Senapedis W, El-Rayes BF, Philip PA, Mohammad RM, Shields AF, Al Hallak MN, Azmi AS. Mol Cancer Ther 22 1422-1433 (2023)
  231. Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts. Rosen JC, Weiss J, Pham NA, Li Q, Martins-Filho SN, Wang Y, Tsao MS, Moghal N. Transl Oncol 14 101179 (2021)
  232. AzidoTMT Enables Direct Enrichment and Highly Multiplexed Quantitation of Proteome-Wide Functional Residues. Ma TP, Izrael-Tomasevic A, Mroue R, Budayeva H, Malhotra S, Raisner R, Evangelista M, Rose CM, Kirkpatrick DS, Yu K. J Proteome Res 22 2218-2231 (2023)
  233. Letter BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. J Hematol Oncol 15 23 (2022)
  234. Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer. Khawaja H, Briggs R, Latimer CH, Rassel M, Griffin D, Hanson L, Bardelli A, Di Nicolantonio F, McDade SS, Scott CJ, Lambe S, Maurya M, Lindner AU, Prehn JHM, Sousa J, Winnington C, LaBonte MJ, Ross S, Van Schaeybroeck S. Mol Cancer Ther 22 135-149 (2023)
  235. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2. Gong Z, Xue L, Vlantis AC, van Hasselt CA, Chan JYK, Fang J, Wang R, Yang Y, Li D, Zeng X, Tong MCF, Chen GG. J Endocrinol Invest (2023)
  236. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer. Prahallad A, Weiss A, Voshol H, Kerr G, Sprouffske K, Yuan T, Ruddy D, Meistertzheim M, Kazic-Legueux M, Kottarathil T, Piquet M, Cao Y, Martinuzzi-Duboc L, Buhles A, Adler F, Mannino S, Tordella L, Sansregret L, Maira SM, Graus Porta D, Fedele C, Brachmann SM. Cancer Res 83 4130-4141 (2023)
  237. CRISPR prime editing for unconstrained correction of oncogenic KRAS variants. Jang G, Kweon J, Kim Y. Commun Biol 6 681 (2023)
  238. Research Support, Non-U.S. Gov't Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC. Cheema PK, Banerji SO, Blais N, Chu QS, Juergens RA, Leighl NB, Sacher A, Sheffield BS, Snow S, Vincent M, Wheatley-Price PF, Yip S, Melosky BL. Curr Oncol 30 6473-6496 (2023)
  239. Case Reports Case Report: Case series: association between blood concentration and side effects of sotorasib. Shigaki R, Yoshida R, Yagita A, Nagasue K, Naraoka T, Nitanai K, Yanada H, Tenma T, Kida R, Umekage Y, Mori C, Minami Y, Sato H, Iwayama K, Hashino Y, Fukudo M, Sasaki T. Front Oncol 13 1269991 (2023)
  240. Chemical evolution of an autonomous DNAzyme with allele-specific gene silencing activity. Nguyen K, Malik TN, Chaput JC. Nat Commun 14 2413 (2023)
  241. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Schulze CJ, Seamon KJ, Zhao Y, Yang YC, Cregg J, Kim D, Tomlinson A, Choy TJ, Wang Z, Sang B, Pourfarjam Y, Lucas J, Cuevas-Navarro A, Ayala-Santos C, Vides A, Li C, Marquez A, Zhong M, Vemulapalli V, Weller C, Gould A, Whalen DM, Salvador A, Milin A, Saldajeno-Concar M, Dinglasan N, Chen A, Evans J, Knox JE, Koltun ES, Singh M, Nichols R, Wildes D, Gill AL, Smith JAM, Lito P. Science 381 794-799 (2023)
  242. Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells. Sugito N, Heishima K, Akao Y. Mol Ther Nucleic Acids 30 49-61 (2022)
  243. Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity. Tokatlian T, Asuelime GE, Naradikian MS, Mock JY, Daris ME, Martin AD, Toledo Warshaviak D, Kamb A, Hamburger AE. Cancer Res Commun 2 58-65 (2022)
  244. Cholesterol Regulates the Tumor Adaptive Resistance to MAPK Pathway Inhibition. Wang XD, Kim C, Zhang Y, Rindhe S, Cobb MH, Yu Y. J Proteome Res 20 5379-5391 (2021)
  245. Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). Lee J, Tan AC, Zhou S, Yoon S, Liu S, Masuda K, Hayashi H, Batra U, Kim DW, Goto Y, Tan SH, Wu YL, Lee DH, Tan DSW, Ahn MJ. JTO Clin Res Rep 3 100261 (2022)
  246. Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer. Thummalapalli R, Bernstein E, Herzberg B, Li BT, Iqbal A, Preeshagul I, Santini FC, Eng J, Ladanyi M, Yang SR, Shen R, Lito P, Riely GJ, Sabari JK, Arbour KC. JCO Precis Oncol 7 e2300030 (2023)
  247. Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation. Wu MY, Zhang EW, Strickland MR, Mendoza DP, Lipkin L, Lennerz JK, Gainor JF, Heist RS, Digumarthy SR. Cancers (Basel) 13 3572 (2021)
  248. Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J, Kulkarni P, Villaflor V, Arvanitis L, Hamilton S, Afkhami M, Pillai R, Armstrong B, Erhunmwunsee L, Massarelli E, Sattler M, Amini A, Salgia R. Cancers (Basel) 14 4933 (2022)
  249. Clinical characteristics and prognosis of pulmonary large cell carcinoma: A population-based retrospective study using SEER data. Xiaochuan L, Jiangyong Y, Ping Z, Xiaonan W, Lin L. Thorac Cancer 11 1522-1532 (2020)
  250. Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Liu SY, Sun H, Zhou JY, Jie GL, Xie Z, Shao Y, Zhang X, Ye JY, Chen CX, Zhang XC, Zhou Q, Yang JJ, Wu YL. Biomark Res 8 22 (2020)
  251. Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP. McFall T, Trogdon M, Guizar AC, Langenheim JF, Sisk-Hackworth L, Stites EC. NPJ Precis Oncol 6 86 (2022)
  252. CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code. Brazel D, Kim J, Ou SI. Lung Cancer (Auckl) 14 31-39 (2023)
  253. CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code. Zhang SS, Lee A, Nagasaka M. Lung Cancer (Auckl) 14 27-30 (2023)
  254. Combinatorial approaches for mitigating resistance to KRAS-targeted therapies. Warren HR, Ross SJ, Smith PD, Coulson JM, Prior IA. Biochem J 479 1985-1997 (2022)
  255. Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam F. Sci Rep 12 1248 (2022)
  256. Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer. Belli S, Pesapane A, Servetto A, Esposito D, Napolitano F, Ascione CM, Allotta A, Zambrano N, Marino FZ, Franco R, Troiani T, Formisano L, Bianco R. Br J Cancer 129 1071-1082 (2023)
  257. Comparison of adequacy between transbronchial lung cryobiopsy samples and endobronchial ultrasound-guided transbronchial needle aspiration samples for next-generation sequencing analysis. Tone M, Inomata M, Awano N, Kuse N, Takada K, Minami J, Muto Y, Fujimoto K, Kumasaka T, Izumo T. Thorac Cancer 12 251-258 (2021)
  258. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome. Shoucair S, Habib JR, Pu N, Kinny-Köster B, van Ooston AF, Javed AA, Lafaro KJ, He J, Wolfgang CL, Yu J. Ann Surg Oncol 29 2720-2731 (2022)
  259. Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images. Pereira T, Freitas C, Costa JL, Morgado J, Silva F, Negrão E, de Lima BF, da Silva MC, Madureira AJ, Ramos I, Hespanhol V, Cunha A, Oliveira HP. J Clin Med 10 (2020)
  260. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition. Vaclova T, Chakraborty A, Sherwood J, Ross S, Carroll D, Barrett JC, Downward J, de Bruin EC. Sci Rep 12 2699 (2022)
  261. Case Reports Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma. De Falco E, Pacini L, Bastianelli D, Spinelli GP, Spoto C, Veltri E, Calogero A. Diagnostics (Basel) 11 659 (2021)
  262. Case Reports Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report. Zelli V, Parisi A, Patruno L, Cannita K, Ficorella C, Luzi C, Compagnoni C, Zazzeroni F, Alesse E, Tessitore A. Front Oncol 12 863639 (2022)
  263. Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors. Davies CW, Oh AJ, Mroue R, Steffek M, Bruning JM, Xiao Y, Feng S, Jayakar S, Chan E, Arumugam V, Uribe SC, Drummond J, Frommlet A, Lu C, Franke Y, Merchant M, Koeppen H, Quinn JG, Malhotra S, Do S, Gazzard L, Purkey HE, Rudolph J, Mulvihill MM, Koerber JT, Wang W, Evangelista M. Nat Biotechnol 40 769-778 (2022)
  264. Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers. Walseng E, Wang B, Yang C, Patel P, Zhao C, Zhang H, Zhao P, Mazor Y. Front Immunol 14 1275304 (2023)
  265. Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion. Sun Z, Zhang H, Zhang Y, Liao L, Zhou W, Zhang F, Lian F, Huang J, Xu P, Zhang R, Lu W, Zhu M, Tao H, Yang F, Ding H, Chen S, Yue L, Zhou B, Zhang N, Tan M, Jiang H, Chen K, Liu B, Liu C, Dang Y, Luo C. Adv Sci (Weinh) 7 2000098 (2020)
  266. Comment Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine. Bhamidipati D, Subbiah V. ESMO Open 8 101591 (2023)
  267. Critical Requirement of SOS1 for Development of BCR/ABL-Driven Chronic Myelogenous Leukemia. Gómez C, Garcia-Navas R, Baltanás FC, Fuentes-Mateos R, Fernández-Medarde A, Calzada N, Santos E. Cancers (Basel) 14 3893 (2022)
  268. Cytosolic Delivery of Small Protein Scaffolds Enables Efficient Inhibition of Ras and Myc. Chan A, Wang HH, Haley RM, Song C, Gonzalez-Martinez D, Bugaj L, Mitchell MJ, Tsourkas A. Mol Pharm 19 1104-1116 (2022)
  269. Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells. Plangger A, Rath B, Hochmair M, Funovics M, Hamilton G. Transl Oncol 14 101230 (2021)
  270. DMA, a Small Molecule, Increases Median Survival and Reduces Radiation-Induced Xerostomia via the Activation of the ERK1/2 Pathway in Oral Squamous Cell Carcinoma. Parashar P, Das MK, Tripathi P, Kataria T, Gupta D, Sarin D, Hazari PP, Tandon V. Cancers (Basel) 14 4908 (2022)
  271. Decrypting Allostery in Membrane-Bound K-Ras4B Using Complementary In Silico Approaches Based on Unbiased Molecular Dynamics Simulations. Castelli M, Marchetti F, Osuna S, F Oliveira AS, Mulholland AJ, Serapian SA, Colombo G. J Am Chem Soc 146 901-919 (2024)
  272. Determinants for Antitumor and Protumor Effects of Programmed Cell Death. Workenhe ST, Inkol JM, Westerveld MJ, Verburg SG, Worfolk SM, Walsh SR, Kallio KLF. Cancer Immunol Res 12 7-16 (2024)
  273. Development and Validation of Targeted Gene Sequencing Panel Based Companion Diagnostic for Korean Patients with Solid Tumors. Min BJ, Lee WS, Seo ME, Lee KH, Jeong SY, Ku JL, Kim YH, Shin SW, Kim JH. Cancers (Basel) 13 5112 (2021)
  274. Development of a versatile HPLC-based method to evaluate the activation status of small GTPases. Araki M, Yoshimoto K, Ohta M, Katada T, Kontani K. J Biol Chem 297 101428 (2021)
  275. Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes. Sato K, Akamatsu H, Koh Y, Ogawa K, Isa SI, Ando M, Tamiya A, Kubo A, Kitagawa C, Kawaguchi T, Yamamoto N. BMC Cancer 22 1148 (2022)
  276. Discovering and Targeting Dynamic Drugging Pockets of Oncogenic Proteins: The Role of Magnesium in Conformational Changes of the G12D Mutated Kirsten Rat Sarcoma-Guanosine Diphosphate Complex. Hu Z, Marti J. Int J Mol Sci 23 13865 (2022)
  277. Discovery of Hit Compounds Targeting the P4 Allosteric Site of K-RAS, Identified through Ensemble-Based Virtual Screening. Gomez-Gutierrez P, Rubio-Martinez J, Perez JJ. J Chem Inf Model 63 6412-6422 (2023)
  278. Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signaling. Lim S, Boyer N, Boo N, Huang C, Venkatachalam G, Angela Juang YC, Garrigou M, Kaan HYK, Duggal R, Peh KM, Sadruddin A, Gopal P, Yuen TY, Ng S, Kannan S, Brown CJ, Verma CS, Orth P, Peier A, Ge L, Yu X, Bhatt B, Chen F, Wang E, Li NJ, Gonzales RJ, Stoeck A, Henry B, Sawyer TK, Lane DP, Johannes CW, Biswas K, Partridge AW. Chem Sci 12 15975-15987 (2021)
  279. Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models. Chen L, Zhang J, Wang X, Li Y, Zhou L, Lu X, Dong G, Sheng C. Acta Pharm Sin B 12 274-290 (2022)
  280. Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Hilzenrat RA, Yip S, Melosky B, Ho C, Laskin J, Sun S, Choi JJ, McGuire AL. Curr Oncol 30 145-156 (2022)
  281. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome. Vendrell JA, Quantin X, Aussel A, Solassol I, Serre I, Solassol J. Transl Lung Cancer Res 10 4084-4094 (2021)
  282. EMab-300 Detects Mouse Epidermal Growth Factor Receptor-Expressing Cancer Cell Lines in Flow Cytometry. Goto N, Suzuki H, Tanaka T, Ishikawa K, Ouchida T, Kaneko MK, Kato Y. Antibodies (Basel) 12 42 (2023)
  283. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Chibaya L, Murphy KC, DeMarco KD, Gopalan S, Liu H, Parikh CN, Lopez-Diaz Y, Faulkner M, Li J, Morris JP, Ho YJ, Chana SK, Simon J, Luan W, Kulick A, de Stanchina E, Simin K, Zhu LJ, Fazzio TG, Lowe SW, Ruscetti M. Nat Cancer (2023)
  284. Editorial Editorial: Oncogenic RAS-Dependent Reprogramming of Cellular Plasticity. Konstantinidou G, Rimessi A. Front Oncol 10 588 (2020)
  285. Editorial Editorial: Ras and Other GTPases in Cancer: From Basic to Applied Research. Cho KJ, Liang JR, Crespo P, Aran V. Front Mol Biosci 8 804818 (2021)
  286. Effects of NRAS Mutations on Leukemogenesis and Targeting of Children With Acute Lymphoblastic Leukemia. Qian J, Li Z, Pei K, Li Z, Li C, Yan M, Qian M, Song Y, Zhang H, He Y. Front Cell Dev Biol 10 712484 (2022)
  287. Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer. Lee C, Jiang ZK, Planken S, Manzuk LK, Ortiz R, Hall M, Noorbehesht K, Ram S, Affolter T, Troche GE, Ihle NT, Johnson T, Ahn Y, Kraus M, Giddabasappa A. Mol Cancer Ther 22 891-900 (2023)
  288. Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population. Peng L, Guo J, Kong L, Huang Y, Tang N, Zhang J, Wang M, He X, Li Z, Peng Y, Wang Z, Han X. Front Oncol 12 1070761 (2022)
  289. Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer. Zhou X, Xiao Q, Fu D, Zhang H, Tang Y, He J, Hu Y, Kong X, Teng F, Liu X, Yuan Y, Ding K. Cancer Biol Med j.issn.2095-3941.2020.0532 (2021)
  290. Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. Bäumer N, Scheller A, Wittmann L, Faust A, Apel M, Nimmagadda SC, Geyer C, Grunert K, Kellmann N, Peipp M, Kailayangiri S, Gutierrez Suburu ME, Strassert CA, Schenk M, Greune L, Rüter C, Dersch P, Hartmann W, Rossig C, Neri D, Müller-Tidow C, Schwöppe C, Schliemann C, Khandanpour C, Lenz G, Berdel WE, Bäumer S. J Hematol Oncol 15 171 (2022)
  291. Editorial Emerging insights to lung cancer drug resistance. Su C. Cancer Drug Resist 5 534-540 (2022)
  292. Enabling synthesis in fragment-based drug discovery (FBDD): microscale high-throughput optimisation of the medicinal chemist's toolbox reactions. Townley C, Branduardi D, Chessari G, Cons BD, Griffiths-Jones C, Hall RJ, Johnson CN, Ochi Y, Whibley S, Grainger R. RSC Med Chem 14 2699-2713 (2023)
  293. Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. Ward AB, Keeton AB, Chen X, Mattox TE, Coley AB, Maxuitenko YY, Buchsbaum DJ, Randall TD, Zhou G, Piazza GA. MedComm (Beijing) 1 121-128 (2020)
  294. Enhancing the Therapeutic Efficacy of KRASG12C Inhibitors in Lung Adenocarcinoma Cell Models by Cotargeting the MAPK Pathway or HSP90. Liu Y, Wu L, Lu H, Wu E, Ni J, Zhou X. J Oncol 2021 2721466 (2021)
  295. Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients. Aran V, Zalis M, Montella T, de Sousa CAM, Ferrari BL, Gil Ferreira C. Medicina (Kaunas) 57 1039 (2021)
  296. Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models. Sisler DJ, Hinz TK, Le AT, Kleczko EK, Nemenoff RA, Heasley LE. Front Oncol 13 1094123 (2023)
  297. Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models. Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K. Transl Oncol 13 100793 (2020)
  298. Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein. Janssen K, Claes F, Van de Velde D, Wehbi VL, Houben B, Lampi Y, Nys M, Khodaparast L, Khodaparast L, Louros N, van der Kant R, Verniers J, Garcia T, Ramakers M, Konstantoulea K, Maragkou K, Duran-Romaña R, Musteanu M, Barbacid M, Scorneaux B, Beirnaert E, Schymkowitz J, Rousseau F. Proc Natl Acad Sci U S A 120 e2214921120 (2023)
  299. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors. Akkapeddi P, Hattori T, Khan I, Glasser E, Koide A, Ketavarapu G, Whaby M, Zuberi M, Teng KW, Lefler J, Maso L, Bang I, Ostrowski MC, O'Bryan JP, Koide S. Proc Natl Acad Sci U S A 120 e2302485120 (2023)
  300. Expression characteristics and their functional role of IGFBP gene family in pan-cancer. Liu Y, Shen S, Yan Z, Yan L, Ding H, Wang A, Xu Q, Sun L, Yuan Y. BMC Cancer 23 371 (2023)
  301. Expression of biogenesis of ribosomes BRX1 is associated with malignant progression and prognosis in colorectal cancer. Ge J, Huang X, Wang P, Lu C. Transl Cancer Res 9 5595-5602 (2020)
  302. Extrinsic KRAS Signaling Shapes the Pancreatic Microenvironment Through Fibroblast Reprogramming. Velez-Delgado A, Donahue KL, Brown KL, Du W, Irizarry-Negron V, Menjivar RE, Lasse Opsahl EL, Steele NG, The S, Lazarus J, Sirihorachai VR, Yan W, Kemp SB, Kerk SA, Bollampally M, Yang S, Scales MK, Avritt FR, Lima F, Lyssiotis CA, Rao A, Crawford HC, Bednar F, Frankel TL, Allen BL, Zhang Y, Pasca di Magliano M. Cell Mol Gastroenterol Hepatol 13 1673-1699 (2022)
  303. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy. Boumelha J, Molina-Arcas M, Downward J. Clin Cancer Res 29 5012-5020 (2023)
  304. Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Feng J, Hu Z, Xia X, Liu X, Lian Z, Wang H, Wang L, Wang C, Zhang X, Pang X. Oncogene 42 1620-1633 (2023)
  305. Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor. Bröker J, Waterson AG, Smethurst C, Kessler D, Böttcher J, Mayer M, Gmaschitz G, Phan J, Little A, Abbott JR, Sun Q, Gmachl M, Rudolph D, Arnhof H, Rumpel K, Savarese F, Gerstberger T, Mischerikow N, Treu M, Herdeis L, Wunberg T, Gollner A, Weinstabl H, Mantoulidis A, Krämer O, McConnell DB, W Fesik S. J Med Chem 65 14614-14629 (2022)
  306. Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options. Huang L, Jiang XL, Liang HB, Li JC, Chin LH, Wei JP, Wang RR, Cai J, Xiong Q, Wang LT, Cram DS, Liu AW. Mol Med 26 88 (2020)
  307. Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. Scharpf RB, Balan A, Ricciuti B, Fiksel J, Cherry C, Wang C, Lenoue-Newton ML, Rizvi HA, White JR, Baras AS, Anaya J, Landon BV, Majcherska-Agrawal M, Ghanem P, Lee J, Raskin L, Park AS, Tu H, Hsu H, Arbour KC, Awad MM, Riely GJ, Lovly CM, Anagnostou V. Cancer Res 82 4058-4078 (2022)
  308. Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP). Es HA, Mahdizadeh H, Asl AAH, Totonchi M. Sci Rep 11 15112 (2021)
  309. Genomic mutation characteristics and prognosis of biliary tract cancer. Guo L, Zhou F, Liu H, Kou X, Zhang H, Chen X, Qiu J. Am J Transl Res 14 4990-5002 (2022)
  310. Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death. Jenkins LJ, Luk IY, Fairlie WD, Lee EF, Palmieri M, Schoffer KL, Tan T, Ng I, Vukelic N, Tran S, Tse JWT, Nightingale R, Alam Z, Chionh F, Iatropoulos G, Ernst M, Afshar-Sterle S, Desai J, Gibbs P, Sieber OM, Dhillon AS, Tebbutt NC, Mariadason JM. Mol Cancer Ther 22 52-62 (2023)
  311. Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target. Wang Y, Zhong B, Xu C, Zhan D, Zhao S, Wu H, Liu M, Lan X, Cai D, Ding Q, Zheng B, Lan J, Lv Q, Wang Y, Qin J. iScience 26 106080 (2023)
  312. HOXA7 promotes the metastasis of KRAS mutant colorectal cancer by regulating myeloid-derived suppressor cells. Dang Y, Yu J, Zhao S, Cao X, Wang Q. Cancer Cell Int 22 88 (2022)
  313. HOXC10 Promotes Metastasis in Colorectal Cancer by Recruiting Myeloid-derived Suppressor Cells. Yu J, Chen X, Zhao S, Jing J, Wang Q, Dang Y. J Cancer 13 3308-3317 (2022)
  314. Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1. Imyanitov EN, Ivantsov AO, Tsimafeyeu IV. Front Oncol 10 549198 (2020)
  315. Hedgehog signalling is involved in acquired resistance to KRASG12C inhibitors in lung cancer cells. Lee C, Yi J, Park J, Ahn B, Won YW, Jeon J, Lee BJ, Cho WJ, Park JW. Cell Death Dis 15 56 (2024)
  316. High expression of MCM10 is predictive of poor outcomes in lung adenocarcinoma. Shao M, Yang S, Dong S. PeerJ 9 e10560 (2021)
  317. How neocarcerand Octacid4 self-assembles with guests into irreversible noncovalent complexes and what accelerates the assembly. Pang YP. Commun Chem 5 9 (2022)
  318. Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen. Wright KM, DiNapoli SR, Miller MS, Aitana Azurmendi P, Zhao X, Yu Z, Chakrabarti M, Shi W, Douglass J, Hwang MS, Hsiue EH, Mog BJ, Pearlman AH, Paul S, Konig MF, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S, Gabelli SB. Nat Commun 14 5063 (2023)
  319. IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells. Rodrigues FS, Miranda VS, Carneiro-Lobo TC, Scalabrini LC, Kruspig B, Levantini E, Murphy DJ, Bassères DS. Int J Mol Sci 21 (2020)
  320. IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma. Wei R, Qi G, Zeng Z, Shen N, Wang Z, Shen H, Gao L, Song C, Ma W, Wang C. Cancer Cell Int 21 620 (2021)
  321. Identification of NRAS Downstream Genes with CRISPR Activation Screening. Tatsumi A, Hirakochi H, Inoue S, Tanaka Y, Furuno H, Ikeda M, Ishibashi S, Taguchi T, Yamamoto K, Onishi I, Sachs Z, Largaespada DA, Kitagawa M, Kurata M. Biology (Basel) 11 1551 (2022)
  322. Identification of EGFR-Related LINC00460/mir-338-3p/MCM4 Regulatory Axis as Diagnostic and Prognostic Biomarker of Lung Adenocarcinoma Based on Comprehensive Bioinformatics Analysis and Experimental Validation. Jia M, Feng S, Cao F, Deng J, Li W, Zhou W, Liu X, Bai W. Cancers (Basel) 14 5073 (2022)
  323. Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. McFall T, Stites EC. Cell Rep 37 110096 (2021)
  324. Identification of a recurrent mosaic KRAS variant in brain tissue from an individual with nevus sebaceous syndrome. Green TE, MacGregor D, Carden SM, Harris RV, Hewitt CA, Berkovic SF, Penington AJ, Scheffer IE, Hildebrand MS. Cold Spring Harb Mol Case Stud 7 a006133 (2021)
  325. Identification of functional substates of KRas during GTP hydrolysis with enhanced sampling simulations. Zeng J, Chen J, Xia F, Cui Q, Deng X, Xu X. Phys Chem Chem Phys 24 7653-7665 (2022)
  326. Identification of the first structurally validated covalent ligands of the small GTPase RAB27A. Jamshidiha M, Lanyon-Hogg T, Sutherell CL, Craven GB, Tersa M, De Vita E, Brustur D, Pérez-Dorado I, Hassan S, Petracca R, Morgan RM, Sanz-Hernández M, Norman JC, Armstrong A, Mann DJ, Cota E, Tate EW. RSC Med Chem 13 150-155 (2022)
  327. Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Khan I, Koide A, Zuberi M, Ketavarapu G, Denbaum E, Teng KW, Rhett JM, Spencer-Smith R, Hobbs GA, Camp ER, Koide S, O'Bryan JP. Cell Rep 38 110322 (2022)
  328. Impact of Sotorasib on the Pharmacokinetics and Pharmacodynamics of Metformin, a MATE1/2K Substrate, in Healthy Subjects. Vuu I, Wahlstrom J, Houk BE. Clin Pharmacokinet 62 267-275 (2023)
  329. In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-Loop, switch I&II regions preventing GTP hydrolysis. Gerber M, Goel S, Maitra R. Comput Biol Med 141 105110 (2022)
  330. Inhibiting a dynamic viral protease by targeting a non-catalytic cysteine. Hulce KR, Jaishankar P, Lee GM, Bohn MF, Connelly EJ, Wucherer K, Ongpipattanakul C, Volk RF, Chuo SW, Arkin MR, Renslo AR, Craik CS. Cell Chem Biol 29 785-798.e19 (2022)
  331. Inhibition mechanism of MRTX1133 on KRASG12D: a molecular dynamics simulation and Markov state model study. Liang F, Kang Z, Sun X, Chen J, Duan X, He H, Cheng J. J Comput Aided Mol Des 37 157-166 (2023)
  332. Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. Padmanabhan J, Saha B, Powell C, Mo Q, Perez BA, Chellappan S. Cancers (Basel) 13 3906 (2021)
  333. Integrated multi-omics characterization of KRAS mutant colorectal cancer. Chong W, Zhu X, Ren H, Ye C, Xu K, Wang Z, Jia S, Shang L, Li L, Chen H. Theranostics 12 5138-5154 (2022)
  334. Integrative Analysis of Pharmacokinetic and Metabolomic Profiles for Predicting Metabolic Phenotype and Drug Exposure Caused by Sotorasib in Rats. Du P, Liu L, Hu T, An Z. Front Oncol 12 778035 (2022)
  335. Interaction between RAS gene and lipid metabolism in cancer. Zhang M, Pan J, Huang P. Zhejiang Da Xue Xue Bao Yi Xue Ban 50 17-22 (2021)
  336. Editorial It's Got Too Greedy. New Therapeutic Options for Metabolic[ally] Addicted NSCLC? Caiola E, Broggini M. Cancers (Basel) 12 E3223 (2020)
  337. KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases. van 't Erve I, Wesdorp NJ, Medina JE, Ferreira L, Leal A, Huiskens J, Bolhuis K, van Waesberghe JTM, Swijnenburg RJ, van den Broek D, Velculescu VE, Kazemier G, Punt CJA, Meijer GA, Fijneman RJA. JCO Precis Oncol 5 PO.21.00223 (2021)
  338. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor. Serna-Blasco R, Sánchez-Herrero E, Sanz-Moreno S, Rodriguez-Festa A, García-Veros E, Casarrubios M, Sierra-Rodero B, Laza-Briviesca R, Cruz-Bermúdez A, Mielgo-Rubio X, Sánchez-Hernández A, Uribelarrea EA, Calvo V, Romero A, Provencio M. ESMO Open 6 100279 (2021)
  339. KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner. Laurent PA, Milic M, Quevrin C, Meziani L, Liu W, Morel D, Signolle N, Clémenson C, Levy A, Mondini M, Deutsch E. J Transl Med 21 773 (2023)
  340. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas. Salmón M, Álvarez-Díaz R, Fustero-Torre C, Brehey O, Lechuga CG, Sanclemente M, Fernández-García F, López-García A, Martín-Guijarro MC, Rodríguez-Perales S, Bousquet-Mur E, Morales-Cacho L, Mulero F, Al-Shahrour F, Martínez L, Domínguez O, Caleiras E, Ortega S, Guerra C, Musteanu M, Drosten M, Barbacid M. J Clin Invest 133 e164413 (2023)
  341. Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. Salem ME, El-Refai SM, Sha W, Puccini A, Grothey A, George TJ, Hwang JJ, O'Neil B, Barrett AS, Kadakia KC, Musselwhite LW, Raghavan D, Van Cutsem E, Tabernero J, Tie J. JCO Precis Oncol 6 e2100245 (2022)
  342. Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer. Yang K, Zhang W, Zhong L, Xiao Y, Sahoo S, Fassan M, Zeng K, Magee P, Garofalo M, Shi L. Cell Death Differ (2023)
  343. Editorial Lung Cancer Organoids as Avatars of Patients With Lung Cancer in the Prediction of Therapeutic Response. Rosell R, Pedraz-Valdunciel C. JTO Clin Res Rep 4 100571 (2023)
  344. MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression. Farnsworth DA, Inoue Y, Johnson FD, de Rappard-Yuswack G, Lu D, Shi R, Ma LIJ, Mattar MS, Somwar R, Ladanyi M, Unni AM, Lockwood WW. NPJ Precis Oncol 6 88 (2022)
  345. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling. Chen N, Tyler LC, Le AT, Welsh EA, Fang B, Elliott A, Davies KD, Danhorn T, Riely GJ, Ladanyi M, Haura EB, Doebele RC. Mol Cancer Ther 23 92-105 (2024)
  346. MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation. Wang Y, Jia Z, Liang C, He Y, Cong M, Wu Q, Tian P, He D, Miao X, Sun B, Yin Y, Peng C, Yao F, Fu D, Liang Y, Zhang P, Xiong H, Hu G. Cell Discov 9 20 (2023)
  347. Mass spectrometry analysis of intact protein N-glycosylation signatures of cells and sera in pancreatic adenocarcinomas. Xu M, Liu Z, Hu W, Han Y, Wu Z, Chen S, Xia P, DU J, Zhang X, Hao P, Xia J, Yang S. J Zhejiang Univ Sci B 25 51-64 (2024)
  348. Mechanism-Based Redesign of GAP to Activate Oncogenic Ras. Berta D, Gehrke S, Nyíri K, Vértessy BG, Rosta E. J Am Chem Soc 145 20302-20310 (2023)
  349. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines. Varshavi D, Varshavi D, McCarthy N, Veselkov K, Keun HC, Everett JR. Metabolomics 16 51 (2020)
  350. MiR-323a regulates ErbB3/EGFR and blocks gefitinib resistance acquisition in colorectal cancer. Zhang Y, Liang S, Xiao B, Hu J, Pang Y, Liu Y, Yang J, Ao J, Wei L, Luo X. Cell Death Dis 13 256 (2022)
  351. MicroRNA-708 emerges as a potential candidate to target undruggable NRAS. Pang JM, Chien PC, Kao MC, Chiu PY, Chen PX, Hsu YL, Liu C, Liang X, Lin KT. PLoS One 18 e0284744 (2023)
  352. Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status. Hsu J, Annunziata JF, Burns E, Bernicker EH, Olsen RJ, Thomas JS. Clin Pathol 15 2632010X221102054 (2022)
  353. Molecular Tumor Board Case Series: Targeting KRAS G12C in Lung Cancer. Gustafson B, Douglass L, Pluard T, Subramanian J. Mo Med 120 314-317 (2023)
  354. Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines. Iezzi A, Caiola E, Colombo M, Marabese M, Broggini M. Am J Cancer Res 10 4488-4497 (2020)
  355. Monoubiquitination of KRAS at Lysine104 and Lysine147 Modulates Its Dynamics and Interaction with Partner Proteins. Nair VV, Yin G, Zhang J, Hancock JF, Campbell SL, Gorfe AA. J Phys Chem B 125 4681-4691 (2021)
  356. Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select. Niu Y, Ferreira Azevedo CA, Li X, Kamali E, Haagen Nielsen O, Storgaard Sørensen C, Frödin M. Nat Genet 54 1983-1993 (2022)
  357. Mutant KRAS-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death. Zhou C, Li W, Liang Z, Wu X, Cheng S, Peng J, Zeng K, Li W, Lan P, Yang X, Xiong L, Zeng Z, Zheng X, Huang L, Fan W, Liu Z, Xing Y, Kang L, Liu H. Nat Commun 15 499 (2024)
  358. Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer. Park YS, Kim J, Ryu YS, Moon JH, Shin YJ, Kim JH, Hong SW, Jung SA, Lee S, Kim SM, Lee DH, Kim DY, Yun H, You JE, Yoon DI, Kim CH, Koh DI, Jin DH. Cancer Biol Ther 24 2246208 (2023)
  359. NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. Iraqi M, Bolel P, Sarkar R, Bhattacharya B, Abu Ahmad M, Edri A, Roisman LC, Elkabets M, Shalata W, Peled N, Porgador A. Int J Mol Sci 23 14054 (2022)
  360. NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis. Sengupta D, Zeng L, Li Y, Hausmann S, Ghosh D, Yuan G, Nguyen TN, Lyu R, Caporicci M, Morales Benitez A, Coles GL, Kharchenko V, Czaban I, Azhibek D, Fischle W, Jaremko M, Wistuba II, Sage J, Jaremko Ł, Li W, Mazur PK, Gozani O. Mol Cell 81 4481-4492.e9 (2021)
  361. Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients. Riera P, Rodríguez-Santiago B, Lasa A, Gonzalez-Quereda L, Martín B, Salazar J, Sebio A, Virgili AC, Minguillón J, Camps C, Surrallés J, Páez D. Cancers (Basel) 12 (2020)
  362. Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. Zhao J, Galvez C, Beckermann KE, Johnson DB, Sosman JA. Expert Rev Precis Med Drug Dev 6 281-294 (2021)
  363. Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2. Kim D, Min D, Kim J, Kim MJ, Seo Y, Jung BH, Kwon SH, Ro H, Lee S, Sa JK, Lee JY. J Exp Clin Cancer Res 42 338 (2023)
  364. Oncogenic Ras cooperates with knockdown of the tumor suppressor Lkb1 by RNAi to override organ size limits in Drosophila wing tissue. Rackley BB, Kiely E, Seong CS, Rupji M, Gilbert-Ross M. MicroPubl Biol 2020 (2020)
  365. Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer. Lo A, McSharry M, Berger AH. BMC Cancer 22 1315 (2022)
  366. Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma. Shen X, Niu N, Xue J. J Transl Int Med 11 322-329 (2023)
  367. Oncogenic dependency plays a dominant role in the immune response to cancer. Li J, D'Amico S, Kirillov V, Petrenko O, Reich NC. Proc Natl Acad Sci U S A 120 e2308635120 (2023)
  368. PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib. Chan CH, Chiou LW, Lee TY, Liu YR, Hsieh TH, Yang CY, Jeng YM. Br J Cancer 128 148-159 (2023)
  369. PDE6D Inhibitors with a New Design Principle Selectively Block K-Ras Activity. Siddiqui FA, Alam C, Rosenqvist P, Ora M, Sabt A, Manoharan GB, Bindu L, Okutachi S, Catillon M, Taylor T, Abdelhafez OM, Lönnberg H, Stephen AG, Papageorgiou AC, Virta P, Abankwa D. ACS Omega 5 832-842 (2020)
  370. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Kim D, Herdeis L, Rudolph D, Zhao Y, Böttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro A, Xue JY, Mantoulidis A, Bröker J, Wunberg T, Schaaf O, Popow J, Wolkerstorfer B, Kropatsch KG, Qu R, de Stanchina E, Sang B, Li C, McConnell DB, Kraut N, Lito P. Nature 619 160-166 (2023)
  371. Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer. Pickles OJ, Drozd A, Tee L, Beggs AD, Middleton GW. Oncotarget 11 3188-3197 (2020)
  372. Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds. Pallara C, Cabot D, Rivas J, Brun S, Seco J, Abuasaker B, Tarragó T, Jaumot M, Prades R, Agell N. Sci Rep 12 15810 (2022)
  373. Perturbation of Autophagy by a Beclin 1-Targeting Stapled Peptide Induces Mitochondria Stress and Inhibits Proliferation of Pancreatic Cancer Cells. Li N, Zhang X, Chen J, Gao S, Wang L, Zhao Y. Cancers (Basel) 15 953 (2023)
  374. Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer. Lee Y, Lee CE, Oh S, Kim H, Lee J, Kim SB, Kim HS. Cancers (Basel) 12 (2020)
  375. Pharmacokinetics, Bioavailability, and Tissue Distribution of the Kirsten Rat Sarcoma Inhibitor Adagrasib in Rats Using UPLC-MS/MS. Lei P, Shen W, Tang H, You L, Chen G, Tang Y, Lu W. Drug Des Devel Ther 18 1-12 (2024)
  376. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations. Oyedele AK, Ogunlana AT, Boyenle ID, Ibrahim NO, Gbadebo IO, Owolabi NA, Ayoola AM, Francis AC, Eyinade OH, Adelusi TI. Mol Divers (2022)
  377. Precision oncology for KRASG12C-mutant colorectal cancer. Di Nicolantonio F, Bardelli A. Nat Rev Clin Oncol (2023)
  378. Pretreatment 18F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer. He P, Zou Y, Qiu J, Yang T, Peng L, Zhang X. J Oncol 2021 6687291 (2021)
  379. Probing RAS Function with Monobodies. Khan I, O'Bryan JP. Methods Mol Biol 2262 281-302 (2021)
  380. Probing the KRas Switch II Groove by Fluorine NMR Spectroscopy. Peacock DM, Kelly MJS, Shokat KM. ACS Chem Biol 17 2710-2715 (2022)
  381. Profile of esophageal squamous cell carcinoma mutations in Brazilian patients. Munari FF, Dos Santos W, Evangelista AF, Carvalho AC, Pastrez PA, Bugatti D, Wohnrath DR, Scapulatempo-Neto C, Guimarães DP, Longatto-Filho A, Reis RM. Sci Rep 11 20596 (2021)
  382. Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands. Noordhof AL, Swart EM, Damhuis RAM, Hendriks LEL, Kunst PWA, Aarts MJ, van Geffen WH. JTO Clin Res Rep 4 100543 (2023)
  383. Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer. Luo X, Peng S, Ding S, Zeng Q, Wang R, Ma Y, Chen S, Wang Y, Wang W. Cancer Cell Int 21 49 (2021)
  384. Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib. Nolan A, Raso C, Kolch W, Kriegsheim AV, Wynne K, Matallanas D. Cancers (Basel) 15 4141 (2023)
  385. RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia. Ren JG, Xing B, Lv K, O'Keefe RA, Wu M, Wang R, Bauer KM, Ghazaryan A, Burslem GM, Zhang J, O'Connell RM, Pillai V, Hexner EO, Philips MR, Tong W. J Clin Invest 133 e165510 (2023)
  386. RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status. Dorard C, Madry C, Buhard O, Toifl S, Didusch S, Ratovomanana T, Letourneur Q, Dolznig H, Garnett MJ, Duval A, Baccarini M. Oncogene 42 1649-1660 (2023)
  387. RGD-p21Ras-scFv expressed prokaryotically on a pilot scale inhibits ras-driven colorectal cancer growth by blocking p21Ras-GTP. Lin P, Qian J, Huang CC, Xu WM, Wang YY, Gao ZR, Zheng SQ, Wang P, Jia DQ, Feng Q, Yang JL. BMC Cancer 24 71 (2024)
  388. Rapid Evaluation of Small Molecule Cellular Target Engagement with a Luminescent Thermal Shift Assay. Mortison JD, Cornella-Taracido I, Venkatchalam G, Partridge AW, Siriwardana N, Bushell SM. ACS Med Chem Lett 12 1288-1294 (2021)
  389. Case Reports Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report. Kunimasa K, Tamiya M, Inoue T, Kawamura T, Nishino K. JTO Clin Res Rep 4 100442 (2023)
  390. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma. Kim JH, Yoon S, Lee DH, Jang SJ, Chun SM, Kim SW. Cancer Med 10 3197-3204 (2021)
  391. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer. Manabe T, Bivona TG. J Clin Invest 132 e156891 (2022)
  392. Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS. Ramalingam PS, Arumugam S. Med Oncol 40 283 (2023)
  393. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome. Pavan A, Bragadin AB, Calvetti L, Ferro A, Zulato E, Attili I, Nardo G, Dal Maso A, Frega S, Menin AG, Fassan M, Calabrese F, Pasello G, Guarneri V, Aprile G, Conte P, Rosell R, Indraccolo S, Bonanno L. Transl Lung Cancer Res 10 202-220 (2021)
  394. SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment. Zhang D, Lindstrom A, Kim EJ, Hwang CI, Hall ML, Lin TY, Li Y. Front Oncol 12 890154 (2022)
  395. Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress. Shimomura I, Watanabe N, Yamamoto T, Kumazaki M, Tada Y, Tatsumi K, Ochiya T, Yamamoto Y. JCI Insight 6 137876 (2021)
  396. Comment Senescence Inflames the Pancreatic Tumor Microenvironment. Petroni G, Galluzzi L. Cell Rep Med 1 100020 (2020)
  397. Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition. Lai LP, Brel V, Sharma K, Frappier J, Le-Henanf N, Vivet B, Muzet N, Schell E, Morales R, Rooney E, Basse N, Yi M, Lacroix F, Holderfield M, Englaro W, Marcireau C, Debussche L, Nissley DV, McCormick F. SLAS Discov 26 922-932 (2021)
  398. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer. Macaya I, Roman M, Welch C, Entrialgo-Cadierno R, Salmon M, Santos A, Feliu I, Kovalski J, Lopez I, Rodriguez-Remirez M, Palomino-Echeverria S, Lonfgren SM, Ferrero M, Calabuig S, Ludwig IA, Lara-Astiaso D, Jantus-Lewintre E, Guruceaga E, Narayanan S, Ponz-Sarvise M, Pineda-Lucena A, Lecanda F, Ruggero D, Khatri P, Santamaria E, Fernandez-Irigoyen J, Ferrer I, Paz-Ares L, Drosten M, Barbacid M, Gil-Bazo I, Vicent S. Nat Commun 14 6332 (2023)
  399. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? Gillson J, Ramaswamy Y, Singh G, Gorfe AA, Pavlakis N, Samra J, Mittal A, Sahni S. Cancers (Basel) 12 (2020)
  400. Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort. Trédan O, Toulmonde M, Le Tourneau C, Montane L, Italiano A, Ray-Coquard I, De La Fouchardière C, Bertucci F, Gonçalves A, Gomez-Roca C, You B, Attignon V, Boyault S, Cassier PA, Dufresne A, Tabone-Eglinger S, Viari A, Sohier E, Kamal M, Garin G, Blay JY, Pérol D. Cancers (Basel) 15 3441 (2023)
  401. Case Reports Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases. Koster KL, Appenzeller C, Lauber A, Früh M, Schmid S. Case Rep Oncol 15 720-725 (2022)
  402. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Nat Med 30 265-270 (2024)
  403. Sotorasib: First Approved KRAS Mutation Inhibitor for the Treatment of Non-small Cell Lung Cancer. De SK. Curr Med Chem 30 1000-1002 (2023)
  404. Stabilization of the RAS:PDE6D Complex Is a Novel Strategy to Inhibit RAS Signaling. Yelland T, Garcia E, Parry C, Kowalczyk D, Wojnowska M, Gohlke A, Zalar M, Cameron K, Goodwin G, Yu Q, Zhu PC, ElMaghloob Y, Pugliese A, Archibald L, Jamieson A, Chen YX, McArthur D, Bower J, Ismail S. J Med Chem 65 1898-1914 (2022)
  405. State-selective modulation of heterotrimeric Gαs signaling with macrocyclic peptides. Dai SA, Hu Q, Gao R, Blythe EE, Touhara KK, Peacock H, Zhang Z, von Zastrow M, Suga H, Shokat KM. Cell 185 3950-3965.e25 (2022)
  406. Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models. Mao B, Guo S. Cancer Res Commun 3 2146-2157 (2023)
  407. Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer. Han J, Xu J, Liu Y, Liang S, LaBella KA, Chakravarti D, Spring DJ, Xia Y, DePinho RA. Genes Dev 37 818-828 (2023)
  408. Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. Chen PY, Huang BJ, Harris M, Boone C, Wang W, Carias H, Mesiona B, Mavrici D, Kohler AC, Bollag G, Zhang C, Zhang Y, Shannon K. JCI Insight 8 e168445 (2023)
  409. Structural basis for the action of the drug trametinib at KSR-bound MEK. Khan ZM, Real AM, Marsiglia WM, Chow A, Duffy ME, Yerabolu JR, Scopton AP, Dar AC. Nature 588 509-514 (2020)
  410. Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine. Wang KB, Liu Y, Li J, Xiao C, Wang Y, Gu W, Li Y, Xia YZ, Yan T, Yang MH, Kong LY. Nat Commun 13 6016 (2022)
  411. Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer. Briseño-Díaz P, Schnoor M, Bello-Ramirez M, Correa-Basurto J, Rojo-Domínguez A, Arregui L, Vega L, Núñez-González E, Palau-Hernández LA, Parra-Torres CG, García Córdova OM, Zepeda-Castilla E, Torices-Escalante E, Domínguez-Camacho L, Xoconostle-Cazares B, Meraz-Ríos MA, Delfín-Azuara S, Carrión-Estrada DA, Villegas-Sepúlveda N, Hernández-Rivas R, Thompson-Bonilla MDR, Vargas M. Life Sci Alliance 6 e202302019 (2023)
  412. Synthesis of Novel Kidney-Type Glutaminase Allosteric Inhibitors Targeting the Critical Lys-320 Residue. Song J, Pan C, Li J, Bai R, Zeng Z, Han Y, Chen Z, Hou W, Li Y, Ruan BH. ACS Med Chem Lett 14 11-17 (2023)
  413. Targeting Nonconserved and Pathogenic Cysteines of Protein Tyrosine Phosphatases with Small Molecules. Bishop AC, Serbina A. Methods Mol Biol 2743 271-283 (2024)
  414. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma. Dasgupta A, Sierra L, Tsang SV, Kurenbekova L, Patel T, Rajapakse K, Shuck RL, Rainusso N, Landesman Y, Unger T, Coarfa C, Yustein JT. Cancer Res 81 199-212 (2021)
  415. Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling. Wang Y, Yao M, Li C, Yang K, Qin X, Xu L, Shi S, Yu C, Meng X, Xie C. Exp Hematol Oncol 12 105 (2023)
  416. Targeting a Pathogenic Cysteine Mutation: Discovery of a Specific Inhibitor of Y279C SHP2. Kim JY, Plaman BA, Bishop AC. Biochemistry 59 3498-3507 (2020)
  417. Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles. Yang L, Li Z, Binzel DW, Guo P, Williams TM. Mol Ther Nucleic Acids 33 559-571 (2023)
  418. Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors. Goebel L, Kirschner T, Koska S, Rai A, Janning P, Maffini S, Vatheuer H, Czodrowski P, Goody RS, Müller MP, Rauh D. Elife 12 e82184 (2023)
  419. The Clinically Actionable Molecular Profile of Early versus Late-Stage Non-Small Cell Lung Cancer, an Individual Age and Sex Propensity-Matched Pair Analysis. McGuire AL, McConechy MK, Melosky BL, English JC, Choi JJ, Peng D, Yee J, Furman BLS, Aguirre Hernandez R, Feijao P, Mulder D, Hughesman C, Yip S. Curr Oncol 29 2630-2643 (2022)
  420. The Genomic Landscape of Colorectal Cancer in the Saudi Arabian Population Using a Comprehensive Genomic Panel. Alsolme E, Alqahtani S, Fageeh M, Barakeh D, Sharma NK, Mangul S, Robinson HA, Fathaddin A, Hauser CAE, Abedalthagafi M. Diagnostics (Basel) 13 2993 (2023)
  421. The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer. Hung PS, Huang MH, Kuo YY, Yang JC. Cancers (Basel) 12 (2020)
  422. Editorial The era of high-quality chemical probes. Licciardello MP, Workman P. RSC Med Chem 13 1446-1459 (2022)
  423. The future of immune checkpoint combinations with tumor-targeted small molecule drugs. Sceneay J, Sinclair C. Emerg Top Life Sci 5 675-680 (2021)
  424. The kinase PLK1 promotes the development of Kras/Tp53-mutant lung adenocarcinoma through transcriptional activation of the receptor RET. Kong Y, Allison DB, Zhang Q, He D, Li Y, Mao F, Li C, Li Z, Zhang Y, Wang J, Wang C, Brainson CF, Liu X. Sci Signal 15 eabj4009 (2022)
  425. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Saturno G, Lopes F, Niculescu-Duvaz I, Niculescu-Duvaz D, Zambon A, Davies L, Johnson L, Preece N, Lee R, Viros A, Holovanchuk D, Pedersen M, McLeary R, Lorigan P, Dhomen N, Fisher C, Banerji U, Dean E, Krebs MG, Gore M, Larkin J, Marais R, Springer C. Ann Oncol 32 269-278 (2021)
  426. The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients. Yang Y, Shen S, Sun Y, Husain H, Zhou H, Lu S, Li Z. Transl Lung Cancer Res 11 213-223 (2022)
  427. The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis. Zhang M, Meng L, Zhang Z, Wu J, Chen X, Wang Y, He J. BMC Med Genomics 15 259 (2022)
  428. Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen. Poole A, Karuppiah V, Hartt A, Haidar JN, Moureau S, Dobrzycki T, Hayes C, Rowley C, Dias J, Harper S, Barnbrook K, Hock M, Coles C, Yang W, Aleksic M, Lin AB, Robinson R, Dukes JD, Liddy N, Van der Kamp M, Plowman GD, Vuidepot A, Cole DK, Whale AD, Chillakuri C. Nat Commun 13 5333 (2022)
  429. Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates. Alcaraz-Sanabria A, Cabañas Morafraile E, Fernández-Hinojal G, Velasco G, Pérez-Segura P, Pandiella A, Győrffy B, Ocaña A. Front Immunol 12 786069 (2021)
  430. Two-Step Covalent Docking with Attracting Cavities. Goullieux M, Zoete V, Röhrig UF. J Chem Inf Model 63 7847-7859 (2023)
  431. Research Support, Non-U.S. Gov't Understanding and drugging RAS: 40 years to break the tip of the iceberg. Brady DC, Hmeljak J, Dar AC. Dis Model Mech 15 dmm049519 (2022)
  432. Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China. Ma Y, Shi H, Zhao G, Liu X, Cai J, Li G, Chen W, Lei Y, Ye L, Fu C, Zhao L, Zhou Y, Huang Y. Front Immunol 14 1012166 (2023)
  433. Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation. Trebino TE, Markusic B, Nan H, Banerjee S, Wang Z. Elife 12 RP88836 (2023)
  434. VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer. Lee YS, Klomp JE, Stalnecker CA, Goodwin CM, Gao Y, Droby GN, Vaziri C, Bryant KL, Der CJ, Cox AD. Genes Cancer 14 30-49 (2023)
  435. Validation of Isoform- and Mutation-Specific RAS Antibodies. Waters AM, Der CJ. Methods Mol Biol 2262 91-103 (2021)
  436. Validation of a small molecule inhibitor of PDE6D-RAS interaction with favorable anti-leukemic effects. Canovas Nunes S, De Vita S, Anighoro A, Autelitano F, Beaumont E, Klingbeil P, McGuinness M, Duvert B, Harris C, Yang L, Pokharel SP, Chen CW, Ermann M, Williams DA, Xu H. Blood Cancer J 12 64 (2022)
  437. Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features. Mendelaar PAJ, Smid M, van Riet J, Angus L, Labots M, Steeghs N, Hendriks MP, Cirkel GA, van Rooijen JM, Ten Tije AJ, Lolkema MP, Cuppen E, Sleijfer S, Martens JWM, Wilting SM. Nat Commun 12 574 (2021)
  438. With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors. Mainardi S. Cell Rep Med 4 100950 (2023)
  439. [Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)]. Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi 23 741-761 (2020)
  440. p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. Ruiz-Patiño A, Rodríguez J, Cardona AF, Ávila J, Archila P, Carranza H, Vargas C, Otero J, Arrieta O, Zatarain-Barrón L, Sotelo C, Ordoñez C, García-Robledo JE, Rojas L, Bermúdez M, Gámez T, Mayorga D, Corrales L, Martín C, Recondo G, Mas L, Samtani S, Ricaurte L, Malapelle U, Russo A, Barrón F, Santoyo N, Rolfo C, Rosell R, ONCOLGroup, CLICaP. Transl Oncol 15 101276 (2021)


Quick links